AP769A - Aralkyl and aralkylidene heterecyclic lactams and imides. - Google Patents

Aralkyl and aralkylidene heterecyclic lactams and imides. Download PDF

Info

Publication number
AP769A
AP769A APAP/P/1997/001107A AP9701107A AP769A AP 769 A AP769 A AP 769A AP 9701107 A AP9701107 A AP 9701107A AP 769 A AP769 A AP 769A
Authority
AP
ARIPO
Prior art keywords
thiomorpholin
benzylidene
disorder
hexahydro
dion
Prior art date
Application number
APAP/P/1997/001107A
Other versions
AP9701107A0 (en
Inventor
Harry Ralph Howard Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701107A0 publication Critical patent/AP9701107A0/en
Application granted granted Critical
Publication of AP769A publication Critical patent/AP769A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.

Description

ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
Background of the Invention
The present invention relates to novel aralkyl and aralkylidene heterocyclic lactams and imides, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention include selective agonists and antagonists of serotonin 1 (5-HT,) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. They are useful in treating or preventing migraine, depression and other disorders for which a 5-HT, agonist or antagonist is indicated.
European Patent Publication 434,561, published on June 26, 1991, refers to 715 alkyl, alkoxy, and hydroxy substituted-1 -(4-substituted-1 -piperazinyl)-naphthalenes. The compounds are referred to as 5-HT, agonists and antagonists useful for the treatment of migraine, depression, anxiety, schizophrenia, stress and pain.
European Patent Publication 343,050, published on November 23, 1989, refers to 7-unsubstituted, halogenated, and methoxy substituted-1 -(4-substituted-1 -piper20 azinyi)-naphthalenes as useful 5-HT,A ligand therapeutics.
PCT publication WO 94/21619, published September 29, 1994, refers to naphthalene derivatives as 5-HT, agonists and antagonists.
PCT publication WO 96/00720, published January 11, 1996, refers to naphthyl ethers as useful 5-HT, agonists and antagonists.
European Patent Publication 701,819, published March 20, 1996, refers to the use of 5-HT, agonists and antagonists in combination with a 5-HT re-uptake inhibitor.
Glennon et ah, refers to 7-methoxy-1-(1-piperazinyl)-naphthalene as a useful 5-HT, ligand in their article 5-HT,D Serotonin Receptors, Clinical Druq Res. Dev,, 22, 25-36 (1991).
Glennon’s article Serotonin Receptors: Clinical Implications, Neuroscience and
Behavioral Reviews, 14, 35-47 (1990), refers to the pharmacological effects associated with serotonin receptors including appetite suppression, thermoregulation, cardiovascular/hypotensive effects, sleep, psychosis, anxiety, depression, nausea, emesis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.
‘ World Patent Application WO 95/31988, published November 30, 1995, refers to the use of a 5-HT,D antagonist in combination with a 5-HT,A antagonist to treat CNS disorders such as depression, generalized anxiety, panic disorder, agoraphobia, social
AP/P/ 9 7/01107
AP. Ο Ο 7 6 9
-2phobias, obsessive-compulsive disorder, post-traumatic stress disorder, memory disorders, anorexia nervosa and bulimia nervosa, Parkinson’s disease, tardive dyskinesias, endocrine disorders such as hyperprolactinaemia, vasospasm (particularly in the cerebral vasculature) and hypertension, disorders of the gastrointestina! tract where changes in motility and secretion are involved, as well as sexual dysfunction.
G. Maura et ak, J. Neurochem, 66 (1), 203-209 (1996), have stated that administration of agonists selective for 5-HT1A receptors or for both 5-HT1A and 5-HT1D receptors might represent a great improvement in the treatment of human cerebellar ataxias, a multifaceted syndrome for which no established therapy is available.
European Patent Publication 666,261, published August 9, 1995 refers to thiazine and thiomorpholine derivatives which are claimed to be useful for the treatment of cataracts.
Summary of the Invention
The present invention relates to compounds of the formula
AP/P/ 9 7/01107 wherein R1 is a group of the formula G1, G2, G3, G4, G5, G6 or G7 depicted below,
I
AP.00769
G6
NR6R9
G3 j
R6
AP/P/ 9 7/01 107
G7 a is zero to eight;
each R13 is, independently, (CrC4)alkyl or a (CrC4)methylene bridge from one of the ring carbons of the piperazine or piperidine ring of G1 or G2, respectively, to the same or another ring carbon or a ring nitrogen of the piperazine or piperidine ring of G1· or G2, respectively, having an available bonding site, or to a ring carbon of R6 having an available bonding site;
E is oxygen, sulfur, SO or SO2;
AP.00769
-4X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C^CJalkyl, hydroxy, trifluoromethyl, (C^-CJalkoxy, -SO,(C.,-C6)alkyl wherein t is zero one or two, -CO2R10 or -CONR11R12;
Y is an optionally substituted (C^-CJ heteroalkyl bridge that, together with the 5 atoms to which it is attached, forms a five to seven membered heterocycle containing two to four heteroatoms selected from the group consisting of 1,3-oxazolidin-4-on-5-yl,
1.3- oxazolidin-2,4-dion-5-yl, 4,5-dihydro-1,2-oxazoiidin-3-on-4-yl, 1,3-thiazolidin-4-on-5yl,1,3-thiazolidin-2,4-dion-5-yl, 1,3-pyrazolidin-4-on-5-yl, 1,3-imidazolidin-2,4-dion-5-yl,
1.2- pyrazolidin-3-on-4-yl, 1,2-th iazo I id in-1,1,3-trion-4-yl, 1,2-thiazolidin-3-on-4-yt, tetrahydro-1,2-oxazin-3-on-4-yl, tetrahydro-1,3-oxazin-4-on-5-yl, tetrahydro-1,3-oxazin2.4- dion-5-yl, morpholin-3-on-2-yl, morpholin-3,5-dion-2-yl, 2,3-dihydro-1,4-oxazin-3on-2-yl, tetrahydro-1,3-thiazin-4-on-5-yl, tetrahydro-1,3-thiazin-2,4-dion-5-yl, tetrahydro-1,2-thiazin-3-on-4-yl, thiomorpholin-3-on-2-yl, thiomorpholin-3,5-dion-2-yI,
2.3- dihydro-1,4-thiazin-3-on-2-yl, hexahydro-1,2-diazin-3-on-4-yl, 4,5-dihydro-2H15 pyridazin-3-on-4-yl, hexahydro-1,3-diazin-4-on-5-yl, hexahydro-1,3-diazin-2,4-dion-5-yl, piperazin-2-on-3-yl, piperazin-2,6-dion-3-yl, tetrahydro-1,3,4-thiadiazin-5-on-6-yl, 5,6dihydro-1,3,4-thiadiazin-5-on-6-yl, 1,3,4-oxadiazin-5-on-6-yl, 5,6-dihydro-1,2,4oxadiazin-5-on-6-yl, tetrahydro-1,2,4-oxadiazin-5-on-6-yl, 1,2,4-triazin-5-on-6-yi, tetrahydro-1,2,4-oxadiazin-5-on-6-yl, 5,6-dihydro-1-2,4-oxadiazin-5-on-6-yl, 1,2,420 oxadiazin-3,5-dion-6-yl, 1,2,4-trazin-6-on-5-yl, hexahydro-1,2-oxazepin-3-on-2-yl, hexahydro-1,3-oxazepin-4-on-5-yl, hexahydro-1,4-oxazepin-3-on-2-yl, hexahydro-1,4oxazepin-3,5-dion-2-yl, hexahydro-1,4-oxazepin-3,5-dion-6-yl, 2,3,5,6-tetrahydro-1-4oxazepin-5,7-dion-6-yl, hexahydro-1,4-oxazepin-5-on-6-yl, hexahydro-1,3-oxazepin2.4- dion-5-yl, hexahydro-1,2-thiazepin-3-on-4-yl, hexahydro-1,4-thiazepin-3-on-2-yl,
2,3,4,5-tetrahydro-1,4-thiazepin-3-on-2-yl, hexahydro-1,4-thiazepin-3,5-dion-2-yl, hexahydro-1,4-thiazepin-3,5-dion-6-yi, 2,3,6,7-tetrahydro-1,4-thiazepin-5-on-6-yl, 6,7dihydro-1,4-thiazepin-5-on-6-yl, hexahydro-1,3-thiazepin-2,4-dion-5-yl, hexahydro-1,2diazepin-3-on-4-yl, hexahydro-1,3-diazepin-2,4-dion-5-yl, hexahydro-1,4-diazepin-2-on3-yl, hexahydro-1,4-diazepin-5-on-6-yl, hexahydro-1,4-diazepin-5,7-dion-6-yl, hexah'ydro-1,3,5-thiadiazepin-3-on-7-yl, 4,5,6,7-tetrahydro-1-3,5-thiadiazepin-6-on-7-yl, •and 2,3,5,6-tetrahydro-1,2,4-triazepin-3,5-dion-7-yl; wherein the substituents on any of the carbon atoms capable of supporting an additional bond, of said (CrC4) heteroalkyl bridge, are chloro, fluoro, (C^CJalkyl, (C^CJalkoxy, trifluoromethy! or
AP/P/ 9 7/01107
AP.00769
-5cyano; wherein the substituents on any of the nitrogen atoms capable of supporting an additional bond, of said (C,-C4) heteroalkyl bridge, are (C^CJalkyl or trifluoromethyl;
R2 is hydrogen, (Ο,-CJalkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (CyC^alkyl, (C^C^alkoxy, trifluoromethyl, cyano and -SO^C^CeJalkyl wherein k is zero, one or two;
R3 is -(CH2)mB, wherein m is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four heteroatoms in the ring, and wherein each of the foregoing phenyl, naphthyl and heteroaryl groups may optionally-be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C^CgJalkyl, (C^Cgjalkoxy, (CrC6) alkoxy-iC,C6)alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, -COOH and -SO^C,C6)alkyl wherein n is zero, one or two;
R6 is selected from the group consisting of hydrogen, (C^Cgjalkyl optionally substituted with (C1-C5)alkoxy or one to three fluorine atoms, or [(C1-C4)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)q-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C^Cgjalkyl, (C.,-C6)alkoxy, trifluoromethyl, cyano and -SO^C^Cgjalkyl, wherein g is zero, one or two;
R7 is selected from the group consisting of hydrogen, (C^Cgjalkyl, [(C,CJalkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroary!-(CH2)r-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and r is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C.,-C6)alkyl, (C,-C6)alkoxy, trifluoromethyl, 30 C(=O)-(C1-C6)aIkyl, cyano and -SOj(C1-C6)alkyl, wherein j is zero, one or two;
or R6 and R7 taken together form a 2 to 4 carbon chain;
R8 is' hydrogen or (C1-C3)alkyl;
Rs is hydrogen or (C^CJalkyl;
AP/P/ 9 7/01107
AP . 0 0 7 6 9
-6or R6 and Rs, together with the nitrogen atom to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen;
and p is one, two, or three;
each of Rw, R11 and R12 is selected, independently, from the radicals set forth in the definition of R2; or R11 and R12, together with the nitrogen to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen; and the broken lines indicate optional double bonds, with the proviso that when the broken line in G2 is a double bond that R8 is absent;
or a pharmaceutically acceptable salt thereof.
The following are more specific embodiments of groups G1 and G2.
AP/P/ 9 7/01 107
AP.00769
AP.00769
-8The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1’-methyle.ne-bis-(2-hydroxy-310 naphthoate)]salts.
The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as Nmethylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
The compounds of this invention include all stereoisomers (e.g,, cis and trans isomers) and all optical isomers of compounds of the formula I (e.g., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers.
The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.
Unless otherwise indicated, the alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.
Preferred compounds of the formula I include those wherein R1 is
AP/P/ 9 7 7 0 1 1 0 7
AP.00769
-9N-R6 ,
Rs is methyl and R2 is hydrogen.
Preferred compounds of the formula I also include those wherein Y, together with the atoms to which it is attached, forms an optionally substituted five to seven membered heterocycle selected from 1,3 thiazolidin-2,4-dion-5-yl, 1,3 imidazoIidin-2,410 dion-5-yl, thiomorpholin-3-on-2-yl or morpholin-3-on-2-yl.
Preferred compounds of the formula I also include those wherein R3 is optionally substituted phenyl or -(CHJ-optionally substituted phenyl.
Examples of specific preferred compounds of the formula I are the following:
3-(4-chlorophenyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-imidazolidine-2,415 dione;
c
3-(4-chlorobenzyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-imidazolidine-2,4. dione;
3- (4-chlorobenzyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiazolidine-2,4dione;
4-benzyl-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one;
4- (3,4-dichlorobenzyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3one;
3- (4-chlorophenyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiazolidine-2,4dione;
3-(4-trifluoromethylphenyl)-5-[2-(4-methylpiperazin-1 -yl)-benzylidene]thiazolidine-2,4-dione;
2-[2-(4-methy Ip iperazin-1 -yI)-benzylidene]-4-(4-trifluoromethylphenyl)thiomorpholin-3-one;
2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one;
' 4-(3,4-dichlorophenyl)-2-[2-fluoro-6-(4-methylpiperazin-1 -yl)-benzylidenejthiPmorphoIin-3-one;
4- (3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-morpholin-3AP/P/ 9 7/01 107 one;
AP.00769
-104-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin3-one;
4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzyl]-thiomorpholin-3-one;
4-methyl-2-[2-(4-metbylpiperazin-1-yl)-benzyIidene]-thiomorpholin-3-one; and
4-(3,4-dichlorophenyl)-2-(2-piperazin-1-ylbenzylidene)-thiomorpholin-3-one.
4-Benzyl-2-[2-(4-methyIpiperazin-1-yl)-benzylidene]-1,1-dioxothiomorpholin-3one;
4-(3,4-Dichlorophenyl)-2-[3-fluoro-2-(4-methylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[5-fluoro-2-(4-methylpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(4-methy Ip iperazin-1-yl)-5-trifluoro methylbenzylidene]-thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-{2-[4-(2-me thoxyethyl)piperazin-1-yl]-benzyiidene}15 thiomprpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(4-isopropylpiperazin-1 -y I)-be nzy I ide ne]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(4-eth ylpiperazin-1-yl)-benzylidene]-thiomorpholin-3one;
4-(4-Chlorophenyl)-2-[2-(4-methylpiperazin-1 -yl)-benzylidene]-thiomorpholin-3one;
4-(3-Chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3one;
2-[2-Chloro-6-(4-methylpiperazin-1-yI)-benzy!idene3-4-(3,4-dichlorophenyl)25 thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(4-methylpiperazin-1 -yl)-4-trifluoromethylbenzylidene]-thiomorpholin-3-one;
4-(3,4-Dichloropheny!)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-1-oxothiomorpholin-3-one;
' 4-(3,4-Dichlorophenyl)-2-(5-fluoro-2-piperazin-1-yl-benzylidene)-thiomorpholin-3•one;
4-(3;4-Dichlorophenyl)-2-[3,6-difluoro-2-(4-methylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
AP/P/ 9 7/01 107
AP.00769
-114-(3,4-Dichlorophenyl)-2-[2-(3,5-d imethy Ip iperazin-1-yl)-be nzylidene]thiomorpholin-3-one;
4-Phenyl-2-[2-(3,4,5-trimethylpiperazin-1-yl)-benzylidene]-thiomorphoiin-3-one;
2-[5-Fluoro-2-(4-methylpiperazin-1-yl)-benzylidene]-4-phenyl-thiornorpholin-35 one;
4- Benzo[1, 3]d ioxo l-5-y 1-2-(2-(3,5-dimethylpiperazin-1-yl)-benzylidene(thiomorphoiin-3-one;
2- [2-(4-tert-Butylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)thiomorpholin-3-one;
3-(3,4-Dichlorophenyl)-5-[2-(4-methylpiperazin-1 -yl)-benzylidene]-thiazolidin-4one;
3- (4-(3,4-Dichlorophenyl)-3-oxo-thiomorpholin-2-ylidenemethyI]-6-dimethylamino2-(4-methylpiperazin-1-yl)-benzonitrile;
5- [2-(4-Methylpiperazin-1-yl)-benzylidene]-2-phenylthiazolidin-4-one;
4-(3,4-Dich!oropheny 1)-2-(2-(3,4,5-trimethylpiperazin-1-yl)-benzylidene]thiomorphoiin-3-one;
4- (3,4-Dichiorophenyl)-2-[5-methyl-2-(4-methylpiperazin-1-yl)-benzylidene]thiomorpho!in-3-one;
2-(4-Chloro-2-(4-methylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)20 thiomorpholin-3-one;
4-(3,4-Difluoropheny!)-2-[2-(3,5-dimethylpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
4-(2,4-Difluoropheny I)-2-[2-(3,5-d imethy I pi perazin- 1-yl)-benzy I idene]thiomorpholin-3-one;
2-[4-Bromo-2-(4-methylpiperazin-1-yl)-ben’zylidene]-4-(3,4-dichloropheriyl)thiomorphoIin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(1-methylpyrrolidin-2-ylmethoxy)-benzylidene]thiomorpholin-3-one;
4-(3,5-Dichlorophenyl)-2-[2-(3,5-d imethy I piperazin-1-y l)-benzy I idene]30 thiom'orpholin-3-one;
4-(3,4-Difluorophenyl)-2-[2-(3,4,5-trimethylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
AP/P/ 9 7/01 107
AP . Ο Ο 7 6 9
-124-(3,4-Dichlorophenyl)-2-[2-(octahydropyrido[1,2-a]pyrazin-2-yl)-benzyiidene]thiomorpholin-3-one;
2-[2-(4-Cyclopropylpiperazin-1-yl)-benzylidene]-4-pyridin-3-yl-thiomorpholin-3one;
2-[2-(4-Cy cl o propy I piperazin-1 -yl)-benzy lidene]-4-(3,4-difluorophenyI)thiomorphoiin-3-one;
2-(2-(4-Cyclo propylpiperazin-1 -yl)-benzylidene]-4-(3,5-dichlorophenyl)thiomorpholin-3-one;
4-(3,4-Difluoropheny I )-2-(2-(2,5-di methy I pipe razi n-1 -y I)-benzyl ide ne]10 thiomorpholin-3-one;
4-(3,5-Dichloropheny 1)-2-(2-(2,5-di methy Ipi pe razin-1 -y I)-be nzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(3-methylaminopyrrolidin-1 -yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Difluoropheny 1)-2-(2-(2,4,5-trimethy lpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;'
4-Benzo[1,3]dioxol-5-yl-2-[2-(4-cyclopropy!piperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
2-(2-(3,5-Dimethylpiperazin-1-yl)-benzyiidene]-4-(4-fluorophenyl)-thiomorpholin-320 one;
4-Benzo[1,3]dioxol-5-y 1-2-(2-(2,5-dimethy lpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
2-(2-(3,5-Dimethylpiperazin-1-yl)-benzylidene]-4-phenylthiomorpholin-3-one; 4-(3,4-Dichlorophenyl)-2-[2-(4-methy lpiperazin-1-yl)-benzylidene]-thiomorpholin25 3-one;
4-(3,4-Dichlorophenyl)-2-[2-(3-dimethylaminopyrrolidin-1-yl)-benzylio'ene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(3-dimethylaminopyrrolidin-1-yl)-benzylidene]thiomorpholin-3-one;
‘ 4-(3,4-Dichlorophenyl)-2-[2-(4-methyl-[1,4]diazepan-1-yl)-benzylidene]1hiomorpholin-3-one;
4-(3,'4-Dichlorophenyl)-2-[2-(2,4,6-trimethy lpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one; and
AP/P/ 97/01107
AP.00769
-132-[2-(4-Cyclopropylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)thiomorph.olin-3-one;
and the pharmaceutically acceptable salts of such compounds.
Other compounds of formula I include the following:
5-[2-(4-methylpiperazin-1-yi)-benzylidene]-thiazoIidine-2,4-dione;
2-[2,4-dibromo-6-(4-methyIpiperazin-1-yl)-benzylidene]-4-(3,4-dichIorophenyl)thiomorpholin-3-one;
4-(4-chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene][1.4] oxazepan-3-one;
4-(4-chlorophenyl)-2-[2-(4-methylpiperazin-1 -yl)-benzylidene][1,4,5]oxadiazepan-3-one;
4-(4-chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene][1.4] thiazepan-3-one;
4-(3,4-dichlorophenyl)-2-{2-[ (2-dimethylaminoethyl)-methyl-aminoj-benzylidene}15 thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-[2-(1-methylpiperidin-4-yl)-benzylidene]-thiomorpholin-3one;
4-(3,4-dichlorophenyl)-2-[2-(1,4-d imethy Ipipe rid in-4-yl)-benzy lid ene]thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholine3,5-dione;
4-(3,4-dichlorophenyl)-2-[2-(2-dimethylaminoethoxy)-benzylidene]-thiomorpholin3-one;
4-(3,4-dichlorophenyl)-2-[2-(4-isopropylpiperazin-1 -yl)-benzylidene]25 thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-[2-(1 -methylpy rrolidin-3-y lmethyl)-benzy lidene]thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-{2-[methyl-(1-methylpyrrolidin-2-ylmethyl)-amino]benzylidene}-thiomorpholin-3-one;
' 4-(3,4-dichlorophenyl)-2-[2-(1-methylpyrrolidin-2-ylmethoxy)-benzylidene]thidmorpholin-3-one;
4-(3,'4-dichlorophenyl)-2-{2-[2-(1-methylpyrrolidin-2-yl)-ethyl]-benzyIidene}thiomorpholin-3-one;
AP/P/ 9 7/01107
AP. Ο Ο 7 6 9
-141- (3,4-dichlorophenyl)-4-methyl-3-[2-(4-methylpiperazin-1-yl)-benzylidenejpiperazin-2-one;
4-methyl-3-[2-(4-methylpiperazin-1-yl)-benzylidene]-1-(4-trifluoromethylphenyl)piperazin-2-one;
1-(4-chlorophenyl)-4-methy!-3-[2-(4-methylpiperazin-1-yl)-benzyiidene]-piperazin2- one;
2- [2-(4-methylpiperazin-1-yl )-benzylidene]-4-(4-trifluoromethylphenyl)-morpholin3- one;
2-[4-fluoro-2-(4-methylpiperazin-1-yl)-benzylidene]-4-(4-trifluoromethyiphenyl)10 thiomorpholin-3-one;
2-[5-fluoro-2-(4-methylpiperazin-1-yl)-benzylidene]-4-(4-trifluoromethylphenyl)thiomorphoiin-3-one;
2- {1-[2-(4-methylpiperazin-1-yl)-phenyl]-ethylidene}-4-(4-trifluoromethylphenyl)thiomorpholin-3-one;
2-[2-(4-methylpiperazin-1 - yi)-benzyl]-4-(4-trifIuoromethylphenyl)-thiomorpholin-3one;
4-(4-chlorophenyl)-6-methyl-2-[2-(4-methylpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
3- (4-chlorophenyl)-2,2-dimethyl-5-[2-(4-methylpiperazin-1-yl)-benzylidene]20 thiazolidin-4-one;
4- (4-chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-[1,4]oxazepan-3one;
4-(4-chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-4H-[1,4]thiazin-3one;
1-(4-chlorophenyl)-4,6,6-trimethyl-3-[2-(4-methylpiperazin-1-yl)-benzylidenejpiperazin-2-one;
1-(4-chlorophenyl)-4-methyl-3-[2-(4-rnethylpiperazin-1-yl)-benzylidene]-piperazin2-one;
4-(4-chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-morpholin-3-one; 30 3-(4-chiorophenyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-oxazolidin-4-one;
3-(4-chlorop henyl)-2,2-dimethyl-5-[2-(4-methylpiperazin-1 -yl)-benzylidenejimidazolidin-4-one; and
3-(4-chlorophenyl)-5-[2-(4-methylpiperazin-1-yl)-berizylidene]-imidazolidin-4-one.
AP/P/ 9 7/01 107
AP . 0 0 7 6 9
-15The present invention also relates to intermediates of the formula
wherein R1 - R3, R6 - R13, G7 - G5, X, Β, Ε, Y, Z, g, j, k, m,· n, p, q, r and t are as defined above.
Examples of specific preferred compounds of formula V are the following:
4-benzyl-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]methyl}-thiomorpholin-3one;
4-(3,4-dichlorobenzyi)-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]methyl}15 thiomorpholin-3-one;
2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]methyl}-4-(4-trifIuoromethylphenyl)thiomorpholin-3-one;
2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]methyl}-thiomorpholin-3-one; 4-(3,4-dichlorophenyl)-2-{[2-fluoro-6-(4-methy lpiperazin-1-yl)-p he nyl]20 hydroxymethyl}-thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]-methyl}morpholin-3-one;
2-{[2,4-dibromo-6-(4-methylpiperazin-1-yl)-phenyl]-hydroxymethyl}-4-(3,4dichlorophenyl)-thiomorpholin-3-one; and
4-(3,4-dichlorophenyl)-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]-methyl}thiomorpholin-3-one.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g,. addictions to alcohol, ***e, heroin, phenolbarbitol, nicotine and benzodiazepines), cluster headache, migraine', pain, Alzheimer’s disease,
AP/P/ 9 7/01 107
AP. Ο Ο 7 6 9
-16obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson’s disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g.. hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer (e.g. small cell lung carcinoma), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph.
The present invention also relates to a method for treating or preventing a disorder orcondition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson’s patients, Postmyocardial Infarction depression, Subsyndromal Symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, ***e, heroin, phenolbarbitol, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, •panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson’s diseases (e.g., dementia in Parkinson’s disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g.,
AP/P/ 9 7/01107
AP.00769
-17hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, (e.g, small cell lung carcinoma), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson’s patients, Postmyocardial Infarction depression, Subsyndromal Symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g,, anorexia nervosa and bulimia nervosa),. obesity, chemical dependencies (e.g., addictions to alcohol, ***e, heroin, phenolbarbitol, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer’s disease, obsessivecompulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related' cognitive decline (ARCD)), Parkinson’s diseases (e.g., dementia in Parkinson’s disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome,
AP/P/ 9 7/01 107
AP.00769
-18trichotillomania, kleptomania, male impotence, cancer (e.g. small cell lung carcinoma), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising a serotonin receptor antagonizing or agonizing effective amount, of a compound of the formula I, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a method for treating or preventing a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson’s patients, Postmyocardial Infarction depression,
Subsyndromal Symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction (e.g., premature ejaculation), eating disorders (e.g., anorexia nervosa and buiimia nervosa), obesity, chemical dependencies (e.g,, addictions to alcohol, ***e, heroin, phenoibarbitol, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson’s diseases (e.g., dementia in Parkinson’s disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer (e.g., small cell lung carcinoma), •chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising administering to a mammal requiring such
AP/P/ 9 7/01 107
AP.00769
-19treatment or prevention a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.
The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to a mammal requiring such treatment or prevention a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.
The present invention relates to a pharmaceutical composition for treating or preventing a condition or disorder that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising:
a) a pharmaceutically acceptable carrier;
b) a compound of the formula I or a pharmaceutically acceptable salt thereof;, and
c) a 5-HT re-uptake inhibitor, preferably sertraline, or a pharmaceutically acceptable salt thereof:
wherein the amount of the active compounds (i.e., the compound of formula I and the 5-HT re-uptake inhibitor) are such that the combination is effective in treating or preventing such disorder or condition.
The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to a mammal requiring such treatment or prevention:
a) a compound of the formula I, defined above, or a pharmaceutically acceptable salt thereof; and
b) a 5-HT re-uptake inhibitor, preferably sertraline, or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds (i.e., the compound of formula I and the 5-HT re-uptake inhibitor) are such that the combination is effective in treating or preventing such disorder or condition.
The present invention also relates to a method for treating or preventing a disorder orcondition that can be treated or prevented by enhancing serotonergic
L 0 I. I 0 / L 6 Idld'J
AP.00769
-20neurotransmission in a mammal, preferably a human, comprising administering to said mammal requiring such treatment or prevention:
a) a 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and
b) a 5-HT1D antagonist of formula I or a pharmaceuticaliy acceptable salt thereof;
wherein the amounts of each active compound (i.e., the 5-HT1A antagonist and the 5-HT1D antagonist) are such that the combination is effective in treating or preventing such disorder or condition.
The present invention also relates to a pharmaceutical composition fortreating 10 or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising:
a) a 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and
b) a 5-HT1D antagonist of formula I or a pharmaceutically acceptable salt thereof;
wherein the amounts of each active compound (i.e., the 5-HT1A antagonist and the 5-HTw antagonist) are such that the combination is effective in treating or preventing such disorder or condition.
Enhanced serotonergic neurotransmission, as used herein, refers to increasing or improving the neuronal process whereby serotonin is released by a pre-synaptic cell upon excitation and crosses the synapse to stimulate or inhibit the post-synaptic cell.
Chemical dependency, as used herein, means an abnormal craving or desire for, or an addiction to a drug. Such drugs are generally administered to the affected individual by any of a variety of means of administration, including oral, parenteral, nasal or by inhalation. Examples of chemical dependencies treatable by the methods of the present invention are dependencies on alcohol, nicotine, ***e, heroin, phenolbarbitol, and benzodiazepines (e.g., Valium (trademark)). Treating a chemical dependency,” as used herein, means reducing or alleviating such dependency.
Sertraline, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1naphthalenamine, as used herein has the chemical formula C17H17NCI2 and the following structural formula
AP/P/ 9 7/01 107
AP.00769
Its synthesis is described in United States Patent 4,536,518, assigned to Pfizer Inc. Sertraline hydrochloride is useful as an antidepressant and anorectic agent, and is also useful in the treatment of depression, chemical dependencies, anxiety obsessive compulsive disorders, phobias, panic disorder, post traumatic stress disorder, and premature ejaculation.
AP/P/ 9 7/01 107
AP.00769
-22Detailed Description of the Invention
Compounds of the formula I may be prepared according to the following reaction schemes and discussion. Unless otherwise indicated, R1 through R3, R6 through R13, G1 through G7, X, Β, Ε, Y, Z, g, j, k, m, n, p, q, r and t and structural formula I in the reaction schemes and discussion that follow are as defined above.
AP/P/ 9 7/01107
AP.00769
AP/P/ 9 7/01 107
AP.00769 <Q
-24SCHEME 2
III
Br, X not =
BOC
P
X
XVIR
r-*
II
G2
R6 (R1
H) σ>
fiu <
AP.00769
-25SCHEME 3
Br
XIV
V
AP/P/ 9 7/01 107
XVI (rM2)
AP. Ο Ο 7 6 9
-26Scheme 1 illustrates a method of synthesizing compounds of the formula I wherein the dashed line represents a double carbon-carbon bond and R1 is a group of the formula G1, G3, G4, G5, G6 or G7. Referring to Scheme 1, a compound of the formula 111, wherein Q is a suitable leaving group (e.g., chloro, fluoro, bromo, mesylate, tosylate, etc.), is reacted with a compound of the formula R1H, wherein H refers to a hydrogen atom on group E or on nitrogen atoms from G1, G3, G5, G6 or G7 and R1 is a group of the formula G1, G3, G4, G5, G6 or G7 in the presence of a base, to form the corresponding compound of formula II. This reaction is generally carried out at a temperature from about 0°C to about 140°C, preferably at aboutthe reflux temperature, in a polar solvent such as dimethyl sulfoxide (DMSO), Ν,Ν-dimethylformamide (DMF), Ν,Ν-dimethylacetamide (DMA) or N-methyl-2-pyrrolidinone (NMP), preferably DMF. Suitable bases include anhydrous sodium carbonate (Na2CO3), potassium carbonate (K2CO3), sodium hydroxide (NaOH) and potassium hydroxide (KOH), as well as amines such as pyrrolidine, triethylamine and pyridine. Anhydrous potassium carbonate is preferred.
Compounds of formula II can be converted into compounds of the formula I, wherein R3 is other than hydrogen, by subjecting them to an aldol condensation or Wittig reaction. For example, in the case of an aldo! condensation, a compound of the formula II can be reacted with a compound of the formula
AP/P/ 9 7/01 107
IV in the presence of a base, to form an aldol intermediate of the formula
AP.00769
-27converted directly in the same reaction which may be isolated or
step to a compound of the formula I by the loss of water. The degree of completion for the conversion of compounds of the formula II to the aldol product of formula I may be assessed using one or more analytical techniques, such as thin layer chromatography (tic) or mass spectrometry. In some instances it may be possible or desirable to isolate the intermediate of formula V. In such case, the compound of formula V may be converted into the compound offormula I by the elimination of water using techniques which are familiar to those skilled in the art, for example, by heating to the reflux temperature a solution of the compound offormula V in a solvent such as benzene, toluene or xylene, in the presence of a catalytic amount of benzene- or p-toluenesuifonic acid with provision for the removal of the water generated. Such water removal techniques may involve the use of molecular sieves or a Dean-Stark trap to isolate the water created as an azeotrope with the solvent.
The aidol reaction is typically carried out in a polar solvent such as DMSO,
DMF, tetrahydrofuran (THF), methanol or ethanol, at a temperature from about-78°C to about 80°C. Preferably, this reaction is carried out in THF at about 25°C. Suitable bases for use in the aldol formation step include potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium hydride (NaH), sodium methoxide, sodium methoxide, potassium-tert.-butoxide, lithium diisopropylamide, pyrrolidine and piperidine. Sodium hydride is preferred. Aldol condensations are described in Modern Synthetic Reactions, Herbert O. House, 2d. Edition, W.A. Benjamin, Menlo Park, California, 629• 682 (1972) and Tetrahedron, 38 (20), 3059 (1982).
AP/P/ 97/01107
Compounds of the formula I, wherein R3 is other than hydrogen, can also be prepared from compounds offormula II by reaction with a compound of the formula IV, wherein R3 is hydrogen or -(C=O)R13, wherein R13 is (C^CJalkyl or trifiuoromethyl, followed by'removal of the -C(=O)R13 group, if present, and reaction with a compound of the formula R3-L' wherein L' is a leaving group and is defined as Q is defined as
AP. Ο Ο 7 6 9
-28above. These reactions can be carried out in a solvent such as di-(alkyl)ether, THF, DMF, DMA or DMSO, preferably DMF, in the presence of a base such as potassium carbonate, sodium carbonate, sodium hydride, potassium hydride, sodium hydroxide or potassium hydroxide, preferably sodium hydride. Reaction temperatures can range from about 0°C to about 150°C, preferably from about 25°C to about the reflux temperature of the solvent.
Alternatively, the compound of formula IV can be converted into a compound of the formula I by means of a Wittig olefination, as described in Helvetica Chimica Acta, 46, 1580 (1963), and depicted below.
//
XI L = (e.g., B r)
Thus, the compound of formula IV can be converted into the corresponding bromide of formula XI using standard bromination conditions, followed by treatment with triphenylphosphine in anhydrous THF to form the intermediate of formula XII. The compound of formula XII can then be treated with a base (e.g., aqueous Na2CO3) to generate the corresponding phosphonium ylide, which can then be reacted with the appropriate intermediate of formula II to produce compounds of general formula I. This transformation is described in A. Maercker, Organic Reactions, 14, 270 (1965).
Compounds of the formula I wherein the dashed line represents a single carboncarbon bond may be prepared by hydrogenating the corresponding compounds wherein the dashed line represents a double carbon-carbon bond, using standard techniques that are well known to those skilled in the art. For example, reduction of the double bond may be effected with hydrogen gas (H2), using catalysts such as palladium on carbon (Pd/C), palladium on barium sulfate (Pd/BaSO4), platinum on carbon (Pt/C), or tris(triphenylphosphine) rhodium chloride (Wilkinson’s catalyst), in an appropriate solvent such as methanol, ethanol, THF, dioxane or ethyl acetate, at a pressure from about 1 to about 5 atmospheres and a temperature from about 10°C to about 60°C,
AP/P/ 9 7/01107
AP.00769
-29as described in Catalytic Hydrogenation in Organic Svnthesis. Paul Rylander, Academic Press Inc., San Diego, 31-63 (1979). The following conditions are preferred: Pd on carbon, methanol at 25°C and 50 psi of hydrogen gas pressure. This method also provides for introduction of hydrogen isotopes (i.e., deuterium, tritium) by replacing 1H2 with 2H2 or 3H2 in the above procedure.
An alternative procedure employing the use of reagents such as ammonium formate and Pd/C in methanol at the reflux temperature under an inert atmosphere (e.g., nitrogen or argon gas) is also effective in reducing the carbon-carbon double bond of compounds of the formula I. Another alternative method involves selective reduction of the carbon-carbon bond. This can be accomplished using samarium and iodine or samarium iodide (Sml2) in methanol or ethanol at about room temperature, as described by R. Yanada et. al., Synlett., 443-4 (1995).
The starting materials of the formulas III and IV are either commercially available or known in the art. For example, compounds of formula III in which R2 is hydrogen are readily available from commercial sources or may be prepared using procedures disclosed in the chemical literature. Compounds of the formula III may also be prepared from the corresponding carboxylic acids or esters, (i.e., formula ill) wherein R2 = OH or O-alkyl), which are commercially available. These acids or esters can be reduced to the corresponding alcohols of formula XIII, depicted below, wherein
Q is defined as for formula III, using one or more of a variety of reducing agents and conditions, depending upon the nature of the substituents Q and X.
Q
AP/P/ 9 7/01 107
Such reducing agents include sodium borohydride (NaBH4), sodium cyanoborohydride 30 (NaCNBH3), lithium aluminum hydride (LiAIHJ and borane in THF (BH3*THF) in solvents such as methanol, ethanol, THF, diethyl ether and dioxane. Oxidation of the alcohol of-formula XIII to the corresponding aldehyde of formula II may be accomplished using a selective oxidizing agent such as Jones reagent (hydrogen
ΑΡ.00769
-30chromate (H2CrO4)), pyridinium chiorochromate (PCC) or manganese dioxide (MnO2). References for such conversions are readily available (e.g., K.B. Wiberg, Oxidation in Organic Chemistry, Part A, Academic Press Inc, N.Y., 69-72 (1965)).
Compounds of the formula IV are also commercially available or can be made by methods well know to those of ordinary skill in the art. Examples of sources of the various compounds of formula IV are presented in Tables 1-3.
TABLE 1
MEMBERED HETEROCYCLES
0
1_1 / 2 \l—R3 r Y=-E-D-)
Name D E Reference
1,3-oxazolidin-4one CH2 O DE 2.339.185; Synthesis, 5. 426-428 (1982); US 2,762,815; Arzneim. Forsch., 27, 766-770 (1977).
1,3-oxazolidin-2,4dione C=O O Parravicini et al., Farmaco Ed.Sci., 31, 49-57 (1976); Kricheldorf, Makromol. Chem., 176, 57-74 (1975).
4,5-dihydro-1,2oxazolidin-3-one O CH2 J. Korean Chem. Soc., 36(3). 453-459 (1992).
1,3-thiazolidin-4one ch2 s EP 626,377; Hansen, Tet. Lett.; 35, (38), 6971-6974 (1994).
1,3-thiazolidin-2,4dione C=O s Marklev, J.A.C.S., 52, 2137-2140 (1930): Dains, J.A.C.S.·, 43, 615 (1921): Barbrv et al., J. Chem. Soc. Perkin Trans. 2, Q), 133-140 (1990); Hansen et al., Tetrahedron Lett., 35, (38). 6971-6974 (1994).
AP/P/ 9 7/01 107
AP.00769
1,3-imidazolidin-4one ch2 NH Fitzi, Anqew. Chem. Int. Ed. Enq.. 25. 345 (1986); J.Het.Chem., 18(5). 963 (1981); Heterocydes, 20(8). 1615 (1983).
1.3- imidazolidin- 2.4- dione C=O NH Ware, Chem. Rev., 46, 403-470 (1950); Freter et al., Justus Liebiqs Ann. Chem.. 607. 174-184 (1957).
1,2-pyrazolidin-3one NH ch2 Japanese Pat. 1,056,161; J.O.C., 40, 3510 (1975); Orq.Synth., 48, 8 (1968).
1,2-thiazoiidin1,1,3-trione SO2 ch2 Rasmussen, et al., Chem. Reviews. 76. 389 (1976).
1,2-thiazolidin-3- one S ch2 Luettrinqhaus et a!., Justus Liebiqs Annal. Chem., 679, 123-135 (1964): Ibid, Anqew. Chem., 76, 51 (1964).
TABLE 2
MEMBERED HETEROCYCLES
0 /
II L. // > \ 3 N-R3 / -K -F-G-K-)
Name F G K Reference
tetrahydro-1,2oxazin-3-one ch2 ch2 0 Khomutov et al., Bull. Acad. Sci. USSR Div. Chem. Sci., 1006-1008 (1962): Nally et al., Tet. Lett., 26, 4107, (1985).
tetrahydro-1,3oxazin-4-one ch2 O ch2 Kalvuskii et al., J. Orq. Chem., 25, (10), 1989-1991 (1989); Linde et al., Arzneim. Forsch., 28, 937-939 (1978).
tetrahydro-1,3- oxaZin-2,4- dione ch2 o c=o Back et al., Tet. Lett., 2651-4 (1977).
AP/P/ 9 7/01 107
AP.0 0 7 6 9
morpholin-3- one O ch2 ch2 U.S. 3,092,630; Australian Patent 9,063,019; Tulyaganov et al., J.O.C.U.S.S.R., (Enq Tran) 6, 13111314 (1970); J.A.C.S., 58, 2338 (1936).
morpholin-3,5- dione O ch2 c=o Hadlev. et al., Tet. Lett, 24(1), 91 (1983).
2.3- dihydro- 1.4- oxazin-3one O ch' CH* Vliet et al., Tetrahedron, 41(101. 20072014 (1985).
tetrahydro-1,3thiazin-4-one ch2 s ch2 Krus et al., Zh.Orq.Khim., 24(8). 1576. (19881; Berqmann et a!., Reel. Trav. Chim. Pavs-Bas., 78. 327-330 (19591: Naqakura et al., Heterocycles, 3, 453 (1975).
tetrahydro-1,3- thiazin-2,4- dione ch2 s C=O Hendrv et al., JACS, 80, 973 (19581: Sohda et al., Chem. Pharm. Bull., 30, 3563 (1982); U.S. 4,352,929.
tetrahydro-1,2thiazin-3-one ch2 ch2 s Kharasch, J.O.C., 28, 1901-1902 (1963).
thiomorpholin- 3-one S ch2 ch2 Davies, J. Chem. Soc., 117, 298-306 (1920).
thiomorpholin- 3,5-dione S ch2 c=o Schulze, Zeitschrift Fur Chem., 182 (1866); Wolfe et al., J.O.C., 35, 3600-7 (1970).
2.3- dihydro- 1.4- thiazin-3- one S ch* CH* Hoio et al., Synthesis, 272 (19791: Masuda et al., Tet. Lett., 32(61 1195 (1991).
hexahydro1,2-diazin-3one ch2 ch2 NH Hwanq et al., Heterocycles, 36(21. 219 (19931: Tavlor et al., J.O.C., 52, 4107 (1987).
4,5-dihydro- 2H-pyridazin- 3-one ch2 CH* N* Reichett et al., Synthesis, 9, 786-787 (1984); Amorosa, Ann. Chim. (Rome), 49, 322-329 (1959).
hexahydro-1,3diazin-4-one ch2 NH ch2 Yamamoto et al., Synthesis, 6, 686, 1985; Skaric et al., Croat. Chem. Acta., 38, 1-4 (1966).
AP/P/ 9 7/01 107
Ring atom is sp2 hybridized. Ring atom is sp2 hybridized.
AP 00769
hexahydro-1,3- diazin-2,4- dione ch2 NH C=O Yamamoto et al., Synthesis, 6, 686. 1985; Zee-Chenq et al., J. Orq. Chem., 26, 1877 (1961); Beckwith et al., J. Chem. Soc., C, 2756 (1968).
piperazin-2- one NH CH2 ch2 E.P. 264,261; J.A.C.S., 51, 3074 (1929); Rees, J. Het. Chem., 24, 1297 (1987); US 3,037,023.
piperazin-2,6- dione NH ch2 c=o J.A.C.S., 51. 3074 (1929): US 3,037,023.
tetrahydro- 1,3,4- thiadiazin-5- one S ch2 NH Japanese Pat. 3,083,972 (1991); Matsubara et al., Chem.Pharm.Bull., 32(4), 1590 (1984).
5,6-dihydro- 1,3,4- thiadiazin-5- one S CH' Ν' Matsubara et al., Chem.Pharm.Bull.. 32(4) 1590 (1984).
1,3,4- oxadiazin-5- one 0 CH2 NH Bennouna, et al., J. Hetero. Chem, 18, 161 (1979).
5,6-dihydro- 1,2,4- oxadiazin-5- one 0 Ν' CH' Japanese Pat. 3,148,267.
tetrahydro- 1,2,4- oxadiazin-5- one 0 NH ch2 Japanese Pat. 3,148,267.
1,2,4-triazin-5one NH NH ch2 Anderson et al., Tet, 39, 3419 (1983): Schulz et al., Chem. Ber., 122. 1983 (1989).
tetrahydro- 1,2,4- oxadiazin-5- one O NH ch2 Hussein. Hetercycles, 26, 163 (1987).
5,6-dihydro- 1,2,.4- oxadiazin-5- o'ne 0 Ν' CH' Hussein, Hetercycles, 26, 163 (1987).
AP/P/ 9 7/01 107
Ring atom is sp2 hybridized.
AP.00769
1,2,4- oxadiazin-3,5- dione 0 NH C=O Raiaqopalan et al., J.C.S. Chem. Commun., 167 (1970).
1,2,4-triazin-6- one NH ch2 NH Anderson et al., Tetrahedron, 39(20). 3419 (1983); Schulz et al., Chem. Ber., 122, 1983 (1989).
AP/P/ 9 7/01107
AP.00769
-35TABLE 3
MEMBERED HETEROCYCLES
0
r^^N-R3
L Q -PZ
IV (Y= -L-M-P-Q-)
Name L M P Q Reference
hexahydro1,2- oxazepin-3- one ch2 ch2 ch2 O Amiaikv et al., Synthesis, 5, 426428, (1982).
hexahydro1,3- oxazepin-4- one ch2 ch2 o ch2 Berqmann et al.. Reel. Trav. Chim. Pays-Bas., 78, 327-330 (1959).
hexahydro1,4- oxazepin-3- one 0 ch2 ch2 ch2 Brown et al., J. Chem. Soc.. Perkin Trans., 1, 557 (1987): Farberow et al., Zh. Obshch. Khim., 25, 133-135 (1955); Grouiller et al., J. Heterocvcl. Chem., 13, 853-859 (1976).
hexahydro- 1.4- oxazepin- 3.5- dione 0 ch2 ch2 c=o See Detailed Description.
2,3,5,6- tetrahydro- 1,4- oxazepin- 5,7-dione C=O 0 ch2 ch2 Brown et al., Synth. Commun., 18, 1801 (1988).
hexahydro- 1,4- oxazepin-5- one ch2 O ch2 ch2 Farberow et al., Zh. Obshch. Khim., 25, 133-135 (1955); Kato et al., Chem. Ph. Bull., 17(12). 2405-2410 (1969).
AP/P/ 97/01 107
AP. Ο Ο 7 6 9
hexahydro- 1.3- . oxazepin- 2.4- dione ch2 ch2 0 c=o See Detailed Description.
hexahydro- 1,2- thiazepin-3- one ch2 ch2 ch2 s Black, J. Chem. Soc. C, 17081710 (1966): Can. J. Chem., 49. 2612-2616 (1971): J. Orq. Chem., 46. 7. 1239-1243 /1981): and J. Orq. Chem., 25, 19531956 (1960); DE 1,195,317.
hexahydro- 1,4- thiazepin-3- one S ch2 ch2 ch2 Hili et al., JACS, 95(9). 29232927 (1973).
2,3,4,5- tetrahydro- 1,4- thiazepin-3- one S CH' CH' ch2 Defoin et al., Helv.Chim.Acta., 68, 1998 (1985).
hexahydro- 1.4- thiazepin- 3.5- dione S ch2 ch2 c=o See Detailed Description.
hexahydro- 1.4- thiazepin- 3.5- dione ch2 s ch2 c=o See Detailed Description.
2,3,6,7- tetrahydro- 1,4- thiazepin-5- one ch2 s ch2 ch2 Jakob et al., Ber. Deutsch Chem. Ges., 96, 88 (1963).
6,7-dihydro- 1,4- thiazepin-5- one ch2 s CH' CH' Yamamoto et al., Anq. Chem. Int. Ed. Enql., 25(7). 635 (1986).
hexahydro- 1.3; thiazepin- 2,4-dione ch2 ch2 s c=o Hanefield et al., Liebiqs Ann. Chem., 4. 337-344 (1992).
AP/P/ 9 7/01 107
Ring bond is sp2 hybridized.
AP.00769
hexahydro- 1,2- diazepin-3- one ch2 ch2 CH2 N Ruties et al.. Tetrahedron Lett., 32, 45, 6629-6632 (1991); and Fritschi et al., Helv. Chem. Acta., 74, 3, 2024-2034 (1991).
hexahydro- 1.3- diazepin- 2.4- dione ch2 ch2 NH C=O Breckenridqe, J.Chem. Res., Miniprint, 6, 166 (1982); Gunawardane, Indian J. Chem. Sect. A, 27, 5, 380-386 (1988).
hexahydro1,4- diazepin-2- one NH ch2 CH2 CH2 U.S. 4,814,443; Poppelsdorf et al., J. Orq. Chem., 26, 131-134 (1961); Zieqler et al., J. Med. Chem., 33, 1, 142-146 (1990).
hexahydro- 1,4- diazepin-5- one ch2 NH ch2 ch2 Crombie et al., J.Chem.Soc. Chem.Commun., 959 (1983): Groves et al., J.A.C.S., 106(3). 630 (1984).
hexahydro- 1,4- diazepin- 5,7-dione C=O N ch2 ch2 Kappe et al., Anqew. Chem. Int. Ed. Enql.. 13, 491 (1974): Bonsiqnore et al., Heterocvcles, 26(6),1619 (1987).
hexahydro1,3,5- thiadiazepin- 2,6-dione S C=O NH ch2 Vass, Synthesis, 10, 817 /1986).
4,5,6,7- tetrahydro- 1,3,5- thiadiazepin- 6-one S CH' Ν' ch2 Vass et al., Synthesis, 10, 817 (1986).
2,3,5,6tetrahydro1,2,4triazepin-3, 5-dione CH' Ν' NH C=O Hasnaoui et al., Rec. Trav. Chim. P.-Bas, 99, 301 (1980).
AP/P/ 9 7/01 107
Ring atom is sp2 hybridized.
AP.00769
-38Compounds of the formula IV, wherein Y is -L-M-P-Q, and L is sulfur or oxygen, M and P are -CH2- and Q is -(0=0)-, can be prepared according to the following procedure. Said compound of the formula IV, depicted below,
IV (Y=L-M-P-Q, L is sulfur or oxygen, M=P= -CH2-, Q= -(C=O)-) wherein L is sulfur or oxygen, is prepared by reacting an anhydride of the formula
AP/P/ 9 7/01107 wherein L is sulfur or oxygen, with an amine of the formula R3NH2 according to the method detailed by Meyers (JOC, 54 (17) 4243 (1989)), Fickenscher (Arch, Pharm,, 307, 520 (1976)) or Cole et al.. (J. Med. Chem., 13, 565 (1970)).
The anhydride of the formula XXXI can be prepared by reacting a diacid of the formula
C02H co2h
XXX
AP.00769
-39wherein L is sulfur or oxygen, with acetic anhydride, according to the methods described in Vogel’s Textbook of Practical Organic Chemistry, 499-501 (4th Ed., Longman House, London UK, 1970).
The compound of the formula XXX is commercially available or can be made 5 according to the procedure of Woodward and Eastman, J.A.C.S., 68, 2229 (1946).
Compounds of the formula IV, wherein Y is -L-M-P-Q, and L and M are carbon, P is oxygen and Q is -(C=O)-, can be prepared according to the following procedure. Said compound of the formula IV, depicted below,
IV (Y=L-M-P-Q, L=M=CH2,' P=oxygen, Q= -(C=O)-) is prepared from a compound of the formula
AP/P/ 9 7/01 107 according to the method described by Back et al., Tet. lett., 2651-:2654 (1977). The ' compound of the formula XXXIV can be prepared according to the method of Ksander, et al., JOC, 42, (7). 1180-1185 (1977).
Compounds of the formula IV, wherein R3 is hydrogen (compounds of the formula IVA), may be alkylated to form the corresponding compounds wherein R3 is not hydrogen using standard techniques available to those skilled in the art, e.g., by (a) generation of the anion of the desired compound of formula IVA using a strong base/polar solvent system such as NaH/THF, NaH/DMF or n-butyllithium/THF (nbuLi/THF), at a temperature from about -30°C to about the reflux temperature of the solvent, for a period of about 5 minutes to about 24 hours, and (b) treatment of the
AP.00769
-40anion with an alkylating agent of the formula R3L' wherein L' is a leaving group such as chloro, bromo, iodo or mesylate. This process is depicted below.
I Vfl (R3=H)
IVB (R3 not = H>
The foregoing conversion of compounds of the formula IVA to those of the formula IVB 15 may also be achieved using phase transfer catalysis conditions as described by
Takahata et al., Heterocycles, 1979, 12(11), pp. 1449-1451.
Compounds of the formula IVB wherein R3 is aryl or heteroaryl can be prepared from compounds of the formula IVA by reaction with an aryl or heteroaryl reagent of the formula R3L', wherein L' is a leaving group such as chloro, bromo or iodo, in the presence of a catalyst such as copper (0) or copper (I) (such as copper, copper-bronze, or copper bromide) and a base, such as sodium hydride, potassium carbonate, or sodium carbonate. The reaction may be run neat or with a polar solvent such as dimethyl formamide, or dimethyl sulfoxide. This reaction, referred to as an Ullmann condensation, is described by Yamamoto & Kurata, Chem. and. Industry, 737-738 (1981).
The compounds of formula R1H used in the preparation of intermediates of the formula II are readily available or may be prepared using standard methods of organic synthesis known to those skilled in the art and adapted from procedures disclosed in the chemical literature. For example, the preparation of compounds of the formula R1H, wherein R1 is G1, may be accomplished using the following reaction sequence, • beginning with commercially available N-tert-butoxycarbonyl piperazine (VI):
AP/P/ 9 7/01 107
C00t-2u COOt-Bu
AP.00769
R6 R6
VI VII G1
Alkylation of the compound of formula VI with a compound of the formula R6L'wherein L' is a leaving group, and is defined as Q is defined above and R6 is (C1-C5)alkyl, aryl(C1-C4)alkyl wherein the aryl moiety is phenyl or naphthyl, or heteroaryl-(CH2)q-, wherein q is zero, one, two, three or four, and the heteroaryl moiety is selected from pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, and benzisothiazolyl, in the presence of an acid scavenger (e.g., sodium bicarbonate (NaHCO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3) or potassium carbonate (K2CO3)), in a polar solvent such as acetone at a temperature of about 10°C to about the reflux temperature of the solvent, will yield the intermediate of formula VII. Removal of the tert-butoxycarbonyl group can be accomplished using acidic conditions, e.g., HBr in acetic acid or trifiuoroacetic acid until the reaction is judged to be complete.
Compounds of the formula II, wherein R1 is tetrahydropyridine or piperidine (i.e.
compounds of the formula G2) and R2 is hydrogen, can be prepared from the 2bromobenzaldehyde of formula III, many of which are commercially available, as depicted in Scheme 2. Referring to Scheme 2, the compound of formula III is first converted into a protected aldehyde of the formula XIV, wherein P represents the entire protected aldehyde or ketone moiety, using methods well known in the art. For example, the 1,3-dioxolane derivative of the aldehyde may be prepared according to the method described by J:E. Cole et al., J. Chem. Soc., 244 (1962), by refluxing a solution of the aldehyde of formula III and 1,3-propanediol in anhydrous benzene with a catalytic amount of p-toluenesulfonic acid. When R2 of formula III is not hydrogen, the ketone can be protected using an appropriate protecting group. Appropriate protecting groups can be chosen from many such groups based on the presence and nature of the substituent X. Examples of suitable protecting groups may be found in
AP/P/ 9 7/01107
AP.00769
-42T.W. Greene and P. Wuts, Protecting Groups in Organic Synthesis, John Wiley & Sons, 2nd Edition, New York, 1991. The most preferred protecting groups are those that are resistant to catalytic hydrogenation (e.g., 1, 3-dioxolane), which would therefore allow for the subsequent reduction, if required, of the carbon-carbon double bond of the tetrahydropyridines of formula XVIA.
Compounds of the formula XIV can then be treated with vinylstannanes of the formula
XV for example, 1-BOC-4-trimethylstannyl-1,2,5,6-tetrahydropyridine (wherein BOC refers to tert-butyloxycarbonyl), in the presence of a catalyst, to form the corresponding compound of formula XVIA. Palladium is the preferred catalyst (for example, ((C6H5)3P)4Pd or Pd2(dba)3), wherein dba refers to dibenzylidene acetone. Suitable solvents for the aforesaid reaction include neat, acetonitrile, dimethylformamide, Nmethyl-2-pyrrolidinone, preferably dimethylformamide. This reaction is conveniently run at about 20°C to about 160°C, preferably about 60°C to about 130°C. This reaction may be carried out as described in Palladium-catalyzed Vinylation of Organic Halides in Organic Reactions, 27, 345-390, (W.G. Dauben, Ed., John Wiley & Sons, Inc., New York, New York , 1982).
Compounds of the formula XVIA can be converted into compounds of the formula II, wherein R1 is tetrahydropyridine by removal of the aldehyde or ketone protecting group. The protecting group for the aldehyde or ketone, P, can be converted into the unprotected ketone or aldehyde of the formula -C(=O)R2 using one or more of the techniques described in Greene, for example, stirring a solution of the -compound of formula XVI in THF and 5% hydrochloric acid at room temperature for 20 hours.
AP/P/ 9 7/01 107
AP.00769
-43Aiternatively, compounds offormula XVIA can be converted into compounds of the formula II, where R1 is piperidine (G2), by catalytic hydrogenation of the tetrahydropyridine of formula XVIA, from the previous paragraph, using standard methods known in the art, generally using palladium on carbon as the catalyst, to form the corresponding compounds offormula XVIB. This reaction is typically performed in an inert solvent, such as ethanol or ethyl acetate, either with or without a protic acid such as acetic acid or hydrochloric acid (HCI). Acetic acid is preferred. The protecting groups on G2 (e.g., BOC) can be removed using one or more of the techniques described in Greene, referred to above, for example, stirring the compound offormula
XVI in ethyl acetate and 3 molar hydrochloric acid at about room temperature for about 30 minutes. The protecting group for the aldehyde or ketone, P, can be converted into the unprotected ketone or aldehyde as described above.
Compounds of the formula XIV from reaction Scheme 2 may also be treated with alkyllithium reagents, for example n-butyllithium, sec-butyllithium or tert15 butyliithium, preferably n-butyllithium in an inert solvent, as shown in Scheme 3, to form the intermediate lithium anion of formula XVII. Suitable solvents for this reaction include, for example, ether or tetrahydrofuran, preferably tetrahydrofuran. Reaction temperatures can range from about -110°C to about 0°C. The intermediate lithium anions offormula XVI! can then be further reacted with a suitable electrophile, selection of which depends on the presence and nature of the substituent. Suitable electrophiles for use in preparing compounds of the formula II wherein R1 is a group of the formula G2 include, for example, carbonyl derivatives or alkylating agents (e.g., 1-BOC-4piperidone). In the case where an aldehyde or ketone is used as the electrophile, the hydroxy group must be removed from the intermediate of formula XVill, as depicted below, in order to form the corresponding compound offormula II.
AP/P/ 9 7/01 107
AP. Ο Ο 7 6 9
-44BOC
XVIII
I I (R1=62)
This step may be accomplished by one of several standard methods known in the art. For example, a thiocarbonyl derivative such as a xanthate may be prepared and removed by free radical processes, both of which are known to those skilled in the art. Alternatively, the hydroxyl group may be removed by reduction with a hydride source such as triethysilane under acidic conditions, using, for example, trifluoroacetic acid or boron trifluoride. The reduction reaction can be performed neat or in a solvent such as methylene chloride. A further alternative would be to first convert the hydroxyl group to a suitable leaving group, such as tosylate or chloride, using standard methods known in the art, and then to remove the leaving group with a nucleophilic hydride, such as, for example, lithium aluminum hydride. The latter reaction is typically performed in an inert solvent such as ether or tetrahydrofuran. Also, a reducing agent may be used to reductively remove the benzylic substituent. Suitable reducing agents include, for example, Raney nickel in ethanol and sodium or lithium in liquid ammonia. Another alternative method for removing the hydroxyl group is to first dehydrate the alcohol of formula XVIII to an olefin of the formula XVIA (i.e. see Scheme 2) with a reagent such as Burgess salt (J. Org. Chem., 38, 26 (1973)) and then to catalytically hydrogenate the double bond under standard conditions with a catalyst such as palladium on carbon.
AP/P/ 9 7/01 107
AP.00769
-45The alcohol may also be dehydrated to the olefin by treatment with acids such as ptoluenesulfonic acid.
Compounds of the formula II, wherein R1 is G2 and R6 is hydrogen, can be converted into the corresponding compounds of the formula II, wherein R1 is G2 and R6 is other than hydrogen, by reacting them with a compound of the formula R6L', as described above in Scheme 1, for preparing compounds of the formula VII.
Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).
The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1’-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
Those compounds of the formula I which are also acidic in nature, e.g., where
R3 includes a COOH or tetrazole moiety, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used
7/01107
AP. 00769
-46as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner ς as before. In either case, stoichiometric quantities of reagents are preferably employed *“ in order to ensure completeness of reaction and maximum product yields.
Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as the active compounds”) are useful Γ** psychotherapeutics and are potent agonists and/or antagonists of the serotonin 1A &
(5-HT1A) and/or serotonin 1D (5-HT1D) receptors. The active compounds are usefui in O>
the treatment of hypertension, depression, generalized anxiety disorder, phobias (e.g., C· agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction (e.g., premature ejaculation), eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, ***e, heroin, phenolbarbitol, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer’s disease, obsessivecompulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson’s diseases (e.g., dementia in Parkinson’s disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving . changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer (e.g. small cell lung carcinoma), chronic paroxysmal hemicrania and headache (associated with vascular disorders).
The'affinities of the compounds of this invention for the various serotonin-1 receptors can be determined using standard radioligand binding assays as described
AP.00769
ATin the literature. The 5-HT,A affinity can be measured using the procedure of Hoyer et ak (Brain Res., 376, 85 (1986)). The 5-HT1D affinity can be measured using the procedure of Heuring and Peroutka (J, Neurosci., 7, 894 (1987)).
The in vitro activity of the compounds of the present invention at the 5-HT1D 5 binding site may be determined according to the following procedure. Bovine caudate tissue is homogenized and suspended in 20 volumes of a buffer containing 50 mM TRIS’hydrochloride (tris[hydroxymethyl]aminomethane hydrochloride) at a pH of 7.7. The homogenate is then centrifuged at 45.000G for 10 minutes. The supernatant is then discarded and the resulting pellet resuspended in approximately 20 volumes of 50 mM TRIS’hydrochloride buffer at pH 7.7. This suspension is then pre-incubated for 15 minutes at 37°C, after which the suspension is centrifuged again at 45.000G for 10 minutes and the supernatant discarded. The resulting pellet (approximately 1 gram) is resuspended in 150 ml of a buffer of 15 mM TRlS*hydrochloride containing 0.01 percent ascorbic acid with a final pH of 7.7 and also containing 10 pM pargyline and
4 mM calcium chloride (CaCl2). The suspension is kept on ice at least 30 minutes prior to use.
The inhibitor, control or vehicle is then incubated according to the following procedure. To 50 μ\ of a 20 percent dimethylsulfoxide (DMSO)/80 percent distilled water solution is added 200 μ\ of tritiated 5-hydroxytryptamine (2 nM) in a buffer of 50 mM TRIS'hydrochloride containing 0.01 percent ascorbic acid at pH 7.7 and also containing 10 μΜ pargyline and4//M calcium chloride, plus 100nM of 8-hydroxy-DPAT (dipropylaminotetraline) and 100 nM of mesulergine. To this mixture is added 750 μ\ of bovine caudate tissue, and the resulting suspension is vortexed to ensure a homogenous suspension. The suspension is then incubated in a shaking water bath for 30 minutes at 25°C. After incubation is complete, the suspension is filtered using glass fiber filters (e.g.. Whatman GF/B-filters™). The pellet is then washed three times with 4 ml of a buffer of 50 mM TRIS»hydrochloride at pH 7.7. The pellet is then placed in a scintillation vial with 5 ml of scintillation fluid (aquasol 2 ™) and allowed to sit overnight. The percent inhibition can be calculated for each dose of the compound.
An IC50 value can then be calculated from the percent inhibition values.
The activity of the compounds of the present invention for 5-HT1A binding ability can be determined according to the following procedure. Rat brain cortex tissue is homogenized and divided into samples of 1 gram lots and diluted with 10 volumes of
AP/P/ 9 7/01 107
AP.00769
-480.32 M sucrose solution. The suspension is then centrifuged at 900G for 10 minutes and the supernate separated and recentrifuged at 70,000G for 15 minutes. The supernate is discarded and the pellet re-suspended in 10 volumes of 15 mM TRIS’hydrochloride at pH 7.5. The suspension is allowed to incubate for 15 minutes at 37°C. After pre-incubation is complete, the suspension is centrifuged at 70,C00G for 15 minutes and the supernate discarded. The resulting tissue pellet is resuspended in a buffer of 50 mM TRIS*hydrochloride at pH 7.7 containing 4 mM of calcium chloride and 0.01 percent ascorbic acid. The tissue is stored at -70°C until ready for an experiment. The tissue can be thawed immediately prior to use, diluted with 10 pm pargyline and kept on ice.
The tissue is then incubated according to the following procedure. Fifty microliters of control, inhibitor, or vehicle (1 percent DMSO final concentration) is prepared at various dosages. To this solution is added 200/jI of tritiated DPAT at a concentration of 1.5 nM in a buffer of 50 mM TRIS*hydrochloride at pH 7.7 containing
4 mM calcium chloride, 0.01 percent ascorbic acid and pargyline. To this solution is then added 750 μ\ of tissue and the resulting suspension is vortexed to ensure homogeneity. The suspension is then incubated in a shaking water bath for 30 minutes at 37°C. The solution is then filtered, washed twice with 4 ml of 10 mM TRIS’hydrochloride at pH 7.5 containing 154 mM of sodium chloride. The percent inhibition is calculated for each dose of the compound, control or vehicle. IC50 values are calculated from the percent inhibition values.
The compounds of formula I of the present invention described in the following Examples were assayed for 5-HT1A and 5-HT1D affinity using the aforementioned procedures. All such compounds of the invention that were tested exhibited IC50’s less than 0.60 μΜ for 5-HT1D affinity and IC50’s less than 1.0 μΜ for 5-HTIA affinity.
The agonist and antagonist activities of the compounds of the invention at 5HT1A and 5-HT1D receptors can be determined using a single saturating concentration according to the following procedure. Male Hartley guinea pigs are decapitated and 5-HT1A receptors are dissected out of the hippocampus, while 5-HT1D receptors are obtained by slicing at 350 mM on a Mcllwain tissue chopper and dissecting out the ‘substantia nigra from the appropriate slices. The individual tissues are homogenized in 5 mM HEPES buffer containing 1 mM EGTA (pH 7.5) using a hand-held glassTeflon® homogenizer and centrifuged at 35,000 x g for 10 minutes at4°C. The pellets
AP/P/ 9 7/01 107
AP.00769
-49are resuspended in 100 mM HEPES buffer containing 1 mM EGTA (pH 7.5) to a final protein concentration of 20 mg (hippocampus) or 5 mg (substantia nigra) of protein per tube. The following agents are added so that the reaction mix in each tube contained 2.0 mM MgCI2, 0.5 mM ATP, 1.0 mM cAMP, 0.5 mM IBMX, 10 mM phosphocreatine,
0.31 mg/mL creatine phosphokinase, 100 μΜ GTP and 0.5-1 microcuries of [32P]-ATP (30 Ci/mmol: NEG-003 - New England Nuclear). Incubation is initiated by the addition of tissue to siliconized microfuge tubes (in triplicate) at 30°C for 15 minutes. Each tube receives 20 pL tissue, 10 μϊ. drug or buffer (at 10X final concentration), 10//L 32 nM agonist or buffer (at 10X final concentration), 20//L forskolin (3 μΜ final concentration) and 40 μϊ. of the preceding reaction mix. Incubation is terminated by the addition of 100 μϊ. 2% SDS, 1.3 mM cAMP, 45 mM ATP solution containing 40,000 dpm [3H]-cAMP (30 Ci/mmol: NET-275 - New England Nuclear) to monitor the recovery of cAMP from the columns. The separation of [32P]-ATP and [32P]-cAMP is accomplished using the method of Salomon et al., Analytical Biochemistry, 1974, 58, 541-548. Radioactivity is quantified by liquid scintillation counting. Maximal inhibition is defined by 10 pM (R)8-OH-DPAT for 5-HT1A receptors, and 320 nM 5-HT for 5-HT1D receptors. Percent inhibitions by the test compounds are then calculated in relation to the inhibitory effect of (R)-8-OH-DPAT for 5-HT1A receptors or 5-HT for 5-HT1D receptors. The reversal of agonist induced inhibition of forskolin-stimulated adenylate cyclase activity is calculated in relation to the 32 nM agonist effect.
The compounds of the invention can be tested for in vivo activity for antagonism of 5-HT1D agonist-induced hypothermia in guinea pigs according to the following procedure.
Male Hartley guinea pigs from Charles River, weighing 250-275 grams on arrival and 300-600 grams at testing, serve as subjects in the experiment. The guinea pigs are housed under standard laboratory conditions on a 7 a.m. to 7 p.m. lighting schedule for at least seven days prior to experimentation. Food and water are available ad libitum until the time of testing.
The compounds of the invention can be administered as solutions in a volume of 1 ml/kg. The vehicle used is varied depending on compound solubility. Test compounds are typically administered either sixty minutes orally (p.o.) or 0 minutes subcutaneously (s.c.) prior to a 5-HT1D agonist, such as [3-(1-methylpyrrolidin-2ylmethyl)-1 H-indol-5-yl]-(3-nitropyridin-3-yl)-amine, which can be prepared as described
AP/P/ 9 7/01 107
AP.00769
-50in PCT publication WO93/111 06, published June 10, 1993 which is administered at a dose of 5.6 mg/kg, s.c. Before a first temperature reading is taken, each guinea pig is placed in a clear plastic shoe box containing wood chips and a metal grid floor and allowed to acclimate to the surroundings for 30 minutes. Animals are then returned to the same shoe box after each temperature reading. Prior to each temperature measurement each animal is firmly held with one hand for a 30-second period. A digital thermometer with a small animal probe is used for temperature measurements. The probe is made of semi-flexible nylon with an epoxy tip. The temperature probe is inserted 6 cm. into the rectum and held there for 30 seconds or until a stable recording is obtained. Temperatures are then recorded.
In p.o. screening experiments, a pre-drug baseline temperature reading is made at -90 minutes, the test compound is given at -60 minutes and an additional -30 minute reading is taken. The 5-HT1D agonist is then administered at 0 minutes and temperatures are taken 30, 60, 120 and 240 minutes later.
In subcutaneous screening experiments, a pre-drug baseline temperature reading is made at -30 minutes. The test compound and 5-HTw agonists are given concurrently and temperatures are taken at 30, 60, 120 and 240 minutes later.
Data are analyzed with two-way analysis of variants with repeated measures in Newman-Keuls post hoc analysis.
The active compounds of the invention can be evaluated as anti-migraine agents by testing the extent to which they mimic sumatriptan in contracting the dog isolated saphenous vein strip [P.P.A. Humphrey et ah, Br. J, Pharmacol., 94, 1128 (1988)]. This effect can be blocked by methiothepin, a known serotonin antagonist. Sumatriptan is known to be useful in the treatment of migraine and produces a selective increase in carotid vascular resistance in the anesthetized dog. The pharmacological basis of sumatriptan efficacy has been discussed in W. Fenwick et ah, Br. J. Pharmacol.. 96. 83 (1989).
The serotonin 5-HT, agonist activity can be determined by the in vitro receptor binding assays, as described for the 5-HT1A receptor using rat cortex as the receptor source and [3H]-8-OH-DPAT as the radioligand [D. Hoyer et al. Eur. J, Pharm., 118, 13 ' (1985)] and as described for the 5-HT1D receptor using bovine caudate as the receptor source and [3H]serotonin as the radioligand [R.E. Heuring and S.J. Peroutka, J.
AP/P/ 0 7/01 107
AP.00769
-51Neuroscience, 7, 894 (1987)]. Of the active compounds tested, all exhibited an IC50 in either assay of 1 //M or less.
The compounds of formula I may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as tricyclic antidepressants (e.g., amitriptyline, dothiepin, doxepin, trimipramine, butripyline, clomipramine, desipramine, imipramine, iprindole, lofepramine, nortriptyline or protriptyline), monoamine oxidase inhibitors (e.g., isocarboxazid, phenelzine or tranylcyclopramine) or5-HT re-uptake inhibitors (e.g., fluvoxamine, sertraline, fluoxetine or paroxetine), and/or with antiparkinsonian agents such· as dopaminergic antiparkinsonian agents (e.g,. levodopa, preferably in combination with a peripheral decarboxylase inhibitor e.g., benserazide orcarbidopa, orwith a dopamine agoniste.g., bromocriptine, lysuride or pergolide). It is to be understood that the present invention covers the use of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof in combination with one or more other therapeutic agents.
Compounds of the formula I and the pharmaceutically acceptable salts thereof, , in combination with a 5-HT re-uptake inhibitor (e.g., fluvoxamine, sertraline, fluoxetine or paroxetine), preferably sertraline, or a pharmaceutically acceptable salt or polymorph thereof (the combination of a compound of formula I with a 5-HT re-uptake inhibitor is referred herein to as the active combination), are useful psychotherapeutics and may be used in the treatment or prevention of disorders the treatment or prevention of which is facilitated by enhanced serotonergic neurotransmission (e.g., hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g.. dementia, amnestic disorders, and age-associated memory impairment), Parkinson’s diseases (e.g., dementia in Parkinson’s disease, neurolepticinduced Parkinsonism and tardive dyskinesias), endocrine disorders (e.g,, hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion) chronic paroxysmal hemicrania and headache (associated with vascular disorders).
Serotonin (5-HT) re-uptake inhibitors, preferably sertraline, exhibit positive activity against depression; chemical dependencies; anxiety disorders including panic
AP/P/ 9 7/01 107
AP.00769
-52disorder, generalized anxiety disorder, agoraphobia, simple phobias, social phobia, and post-traumatic stress disorder; obsessive-compulsive disorder; avoidant personality disorder and premature ejaculation in mammals, including humans, due in part to their ability to block the synaptosomal uptake of serotonin.
United States Patent 4,536,518 describes the synthesis, pharmaceutical composition and use of sertraline for depression and is hereby incorporated by reference in its entirety.
Activity of the active combination as antidepressants and related pharmacological properties can be determined by methods (1)-(4) below, which are ' described in Koe, B. et al., Journal of Pharmacology and Experimental Therapeutics, 226 (3), 686-700 (1983). Specifically, activity can be determined by studying (1) their ability to affect the efforts of mice to escape from a swim-tank (Porsolt mouse behavior despair test), (2) their ability to potentiate 5-hydroxytryptophan-induced behavioral symptoms in mice in vivo, (3) their ability to antagonize the serotonin-depleting activity of p-chloroamphetanjine hydrochloride in rat brain in vivo, and (4) their ability to block the uptake of serotonin, norepinephrine and dopamine by synaptosomal rat brain cells in vitro. The ability of the active combination to counteract reserpine hypothermia in mice in vivo can be determined according to the methods described in U.S. Pat. No. 4,029,731.
The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or· hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting 'agents (e.g,, sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product
L 0 I I 0 / L 6 /d/dV
AP.00769
-53for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g,, almond oil, oily esters or ethyl alcohol); and preservatives (e.g,, methyl or propyl phydroxybenzoates or sorbic acid).
For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner.
The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g,, containing conventional suppository bases such as cocoa butter or other glycerides.
For. intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions
AP/P/ 9 7/01 107
AP.00769
-54referred to above (e.g., depression) is 0.1 to 200 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
Aerosol formulations for treatment of the conditions referred to above (e.g., migraine) in the average adult human are preferably arranged so that each metered dose or “puff’ of aerosol contains 20//g to 1000//g of the compound of the invention. The overall daily dose with an aerosol will be within the range 100//g to 10 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
In connection with the use of an active compound of this invention with a 5-HT re-uptake inhibitor, preferably sertraline, for the treatment of subjects possessing any of the above conditions, it is to be noted that these compounds may be administered either alone or in combination with pharmaceuticaliy acceptable carriers by either of the routes previously indicated, and that such administration can be carried out in both single and multiple dosages. More particularly, the active combination can be administered in a wide variety of different dosage forms, i.e,, they may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspension, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, such oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for such purposes. In general, the compounds of formula I are present in such dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, i.e., in amounts which are sufficient to provide the desired unit dosage and a 5-HT re-uptake inhibitor, preferably sertraline, is present in such dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, i.e., in amounts which are sufficient to provide the desired unit dosage.
A proposed daily dose of an active compound of this invention in the combination formulation (a formulation containing an active compound of this invention and a 5-HT re-uptake inhibitor) for oral, parenteral, rectal or buccal administration to 'the average adult human for the treatment of the conditions referred to above is from about 0.01 mg to about 2000 mg, preferably from about 0.1 mg to about 200 mg of the /01 10//6 /d/dV
AP.00769
-55active ingredient of formula I per unit dose which could be administered, for example, 1 to 4 times per day.
A proposed daily dose of a 5-HT re-uptake inhibitor, preferably sertraline, in the combination formulation for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.1 mg to about 2000 mg, preferably from about 1 mg to about 200 mg of the 5-HT re-uptake inhibitor per unit dose which could be administered, for example, 1 to 4 times per day.
A preferred dose ratio of sertraline to an active compound of this invention in the combination formulation for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.00005 to about 20,000, preferably from about 0.25 to about 2,000.
Aerosol combination formulations for treatment of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or “puff’ of aerosol contains from about 0.01 //g to about 100 mg of the active compound of this invention, preferably from about 1 //g to about 10 mg of such compound. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
Aerosol formulations for treatment of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or “puff’ of aerosol contains from about 0.01 mg to about 2000 mg of a 5-HT re-uptake inhibitor, preferably sertraline, preferably from about 1 mg to about 200 mg of sertraline. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
As previously indicated, a 5-HT re-uptake inhibitor, preferably sertraline, in combination with compounds of formula I are readily adapted to therapeutic use as antidepressant agents. In general, these antidepressant compositions containing a 5-HT re-uptake inhibitor, preferably sertraline, and a compound of formula I are normally administered in dosages ranging from about 0.01 mg to about 100 mg per kg of body weight per day of a 5-HT re-uptake inhibitor, preferably sertraline, preferably from about
0.1 mg. to about 10 mg per kg of body weight per day of sertraline; with from about
0.001 mg. to about 100 mg per kg of body weight per day of a compound of formula I, preferably from about 0.01 mg to about 10 mg per kg of body weight per day of a
AP/P/ 9 7/01107
AP 00769
-56compound of formula I, although variations will necessarily occur depending upon the conditions of the subject being treated and the particular route of administration chosen.
The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (d) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Specific rotations were measured at room temperature using the sodium D line (589 nm). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to Ν,Ν-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 //m silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room or ambient temperature refers to 20-25°C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. Concentration at reduced pressure means that a rotary evaporator was used.
Example 1
3-(4-Chlorobenzyl)-5-r2-(4-methylpiperazin-1 -yQ-benzylidene'l-imidazolidine2,4-dione
Under a nitrogen atmosphere in a flame-dried flask, sodium hydride (43 mg, 1.07 mmol, 60% oil dispersion) was washed with hexanes and then treated with tetrahydrofuran (THF) (8 mL), followed by 3-(4-chlorobenzyl)-imidazolidine-2,4-dione (235 mg, 1.04 mmol) and 2-(4-methylpiperazin-1-yl)-benzaldehyde (209 mg, 1.02 mmol), and an additional 2 mL of THF. After refluxing the mixture overnight, the solvent was removed and the residue was treated with aqueous ammonium chloride and aqueous sodium bicarbonate to a pH of 8, then extracted with methylene chloride. The organic extracts were washed with aqueous sodium chloride, dried and concentrated in vacuo to a yellow foam. The foam was crystallized from hot ethyl acetate : hexanes to give a solid, 240 mg (57%).
M.p. 185-187°C. Mass spectrum: 411 (M+1). 1H-NMR (CDCI3) δ 9.45 (1H, s), 7.37-7.24 (4H, m), 7.16-7.09 (2H, m), 6.72 (1H, s), 4.72 (2H, s), 3.02 (4H, br s), 2.34 (3H, 2). Elemental analysis calculated for C22H23N402ClO.5 H2O: C 62.93, H 5.76, N
13.34' Found: C 63.33, H 5.58, N 13.58.
The following examples were prepared by an analogous procedure to that of Example 1,‘except where indicated.
AP/P/ 9 7/01 107
AP.00769
-57Example 2
3-(4-Chlorophenvl)-5-r2“(4-methvlpiperazin-1-yl)-benzvlidene1-imidazo[idine2,4-dione
M.p. 193-193.5°C. Mass spectrum 397 (M+1). Elemental analysis calculated for 5 C21H21N4O2CI’0.5 CH3CN: C 63.31, H 5.43, N 15.10. Found: C 62.93, H 5.50, N 15.10.
Example 3
3-(4-Chlorobenzvl)-5-r2-(4-methylpiperazin-1-vl)-benzvlidenelthiazolidine-2,4-dione hydrochloride hydrate
M.p. 240-242°C. Mass spectrum 428 (M+1). Elemental analysis calculated for 10 C22H22N3O2SCI-HCI-0.25 H2O: C 56.35, H 5.05, N 8.96. Found: C 56.18, H 5.03, N 8.70.
Example 4
4-Benzvl-2-f2-(4-methvlpiperazin-1-vl)-benzvlidenel-thiomorphoIin-3-one
M.p. 106-108°C. Mass spectrum 394 (M+1). Elemental analysis calculated for C23H27N3OS: C 70.20, H 6.91, N 10.68. Found: C 70.19, H 6.99, N 10.72. 1H-NMR (CDCIJ (5 8.10 (1H, s), 7.64 (1H, dd), 7.53-7.26 (6H, m), 7.08-6.97 (2H, m), 4.80 (2H, s), 3.69 (2H, sym m), 3.01 (4H,' t), 2.88 (2H, sym m), 2.63 (4H, br s), 2.38 (3H, s).
Example 5
4-(3,4-Dichlorobenzyl)-2-r2-(4-methvlpipe razin-1-yl)-benzvlidene1-thiomorpholin-3one hydrochloride dihydrate
M.p. 90-115°C. Mass spectrum 462 (M+1). Elemental analysis calculated for
C23H25N3OSCI2-HCI-2 H2O: C 51.64, H 5.65, N 7.86. Found: C 51.83, H 5.76, N 7.64.
Example 6
5-i2-(4-Methvlpiperazin-1-vl)-benzylidene1-thiazoiidine-2,4-dione hemihydrate
Yellow solid, m.p. 105°C (dec.). Mass spectrum 304 (M+1). Elemental analysis 25 calculated for C15Hl7N3O2S-0.5 H2O: C 57.67, H 5.81, N 13.45. Found: C 57.81, H 6.48, N 13.20. 1H-NMR (CDCI3 400 MHz) δ 8.05 (1H, s), 7.68 (1H, d), 7.36 (1H, dt),
7.12-7.03 (2H, m), 3.12-3.02 (5H, m), 2.71 (4H, br s), 2.41 (3H, s).
L 0 I I 0 / L 6 /d/dV
AP.00769
-58Example 7
3-(4-Chlorophenyl)-5-r2-(4-methvlpiperazin-1-yl)-benzvlidene1-thiazolidine2,4-dione hydrochloride hemihydrate
Under a nitrogen atmosphere in a flame-dried flask, a mixture of
3-(4-chlorophenyl)-thiazolidine-2,4-dione (158 mg, 0.694 mmol),
2- (4-methylpiperazin-1-yl)-benzaldehyde (142 mg, 0.694 mmol) and sodium acetate (171 mg, 2.08 mmol) in 1 mL of glacial acetic acid was heated to reflux for approximately 6 hours and cooled to room temperature. Saturated aqueous sodium carbonate (Na2CO3) was added until the pH was about 10. and the mixture was extracted several times with methylene chloride. The organic layers were washed with brine, saturated sodium chloride, dried and evaporated to a brown solid which was recrystallized from ethyl acetate.
M.p. 187-189°C. Elemental analysis calculated for C21H20N3O2CIS: C 60.94, H 4.87, N 10.15. Found: C 60.57, H 4.95, N 10.00.
The above compound ( 56 mg) was treated with diethyl ether saturated with hydrogen chloride gas and the product was recrystallized from hot ethanol to yield
3- (4-chlorophenyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiazolidine-2,4-dione hydrochloride hemihydrate as a solid, 54 mg, m.p. 254-258 “C.
Elemental analysis calculated for C21H20N3O2CIS*HCI-0.5 H2O: C 54.90, H 4.83,
N 9.15. Found: C 55.07, H 5.01, N 8.78. Ή-NMR (DMSO-d6) δ 10.84 (1H, brs), 7.60 (2H, d), 7.52-7.45 (4H, m), 7.24 (2H, t), 3.53-3.05 (8H, m), 2.80 (3H, s).
The following examples were prepared by an analogous procedure to that of Example 7, except as indicated.
Example 8
3-(4-|T rifluoromethvn-phenyl)-5-i2-(4-methvlpiperazin-1 -yl)benzylidenel- thiazolidine-2,4-dione hydrochloride dihydrate
M.p. 159-177°C. Mass spectrum 448 (M+1). Elemental analysis calculated for C22H20N3O2SF3-HCl-2 H2O: C 50.82, H 4.85, N 8.08. Found: C 51.04, H 4.66, N 8.01.
i*· c
c r* cr.
a a
<
AP.00769
-59Example 9
2-[2-(4-Methvlpiperazin-1-vl)-benzvlidene1-4-(4-trifluoromethvlphenyl)thiomorpholin-3-one hydrochloride trihydrate M.p. 128-134°C. Mass spectrum 448 (M+1). 1H-NMR (DMSO-d6, 400 MHz) δ
10.66 (1H, br s), 7.79 (1H, s), 7.76 (2H, d), 7.66 (1H, d), 7.61 (2H, d), 7.34 (1H, t),
7.15-7.10 (2H, m), 4.14 (2H, m), 3.43 (2H, br s), 3.22 (2H, m), 3.21-3.00 (6H, m), 2.78 (3H, s).
Example 10
2-r2-(4-Methvlpiperazin-1-vl)-benzylidene]-thiomorpholin-3-one
Sodium hydride (930 mg, 23.3 mmol of 60% oil dispersion) was washed with hexanes under a nitrogen atmosphere and suspended in 100 mL of anhydrous THF. Thiomorphoiin-3-one (1.0 g, 8.55 mmol) was added, followed immediately by 2-(4methylpiperazin-1-yl)-benzaldehyde (1.58 g., 7.75 mmol). The reaction was then heated to reflux overnight, cooled to room temperature and concentrated in vacuo. The residue was dissolved in methylene chloride and washed with aqueous ammonium chloride (NH4CI) and saturated brine and then dried with MgSO4. Purification using flash chromatography gave 2-{hydroxy-[2-(4-methylpiperazin-1-yl)phenyl]-methyl}thiomorpholin-3-one as a white solid, m.p. 137-139°C. Mass spectrum 322 (M+1).
A mixture of 190 mg (0.6 mmol) of the preceding intermediate in 25 mL of toluene was treated with 135 mg (0.71 mmol) of p-toluenesulfonic acid and refluxed overnight with a Dean-Stark condenser to collect the water which azeotroped. After cooling, the solvent was removed and the residue was dissolved in methylene chloride, washed with saturated aqueous sodium carbonate (Na2CO3) and saturated brine, dried with magnesium sulfate and concentrated in vacuo to a brown foam. The free base was crystallized from ethyl acetate/hexanes to yield a crystalline solid.
M.p. 133-135°C; mass spectrum 304 (M+1). Elemental analysis calculated for
C16H21N3OS: C 63.34, H 6.98, N 13.85. Found: C 63.17, H 7.12, N 13.67
The following examples were prepared by an analogous procedure to Example
10, except where indicated.
Example 11
4-(3,4-Dichlorophenvl)-2-r2-fluoro-6-(4-methvlpiperazin-1-vl)-benzylidene1thiomorphoiin-3-one
M.p. 146-147°C. Mass spectrum 466 (M+1), 468.
AP/P/ 9 7/01 107
AP.00769
-60Example 12
4-(3,4-Dichlorophenyl)-2-F2-(4-methylp iperazin-1-yl)-benzylidene1-morpholin-3-one
M.p. 169-171 °C (decomp.). Mass spectrum 432 (M+), 434, 436.
Example 13
2-r2,4-Dibromo-6-(4-methylpiperazin-1-vl)-benzvlidene1-4-(3,4-dichlorophenvl)thiomorpholin-3-one.
M.p. 166-168°C. Mass spectrum 607 (M+1). Elemental analysis calculated for C22H21N3OSBr2: C 43.59, H 3.49, N 6.93. Found: C 43.56, H 3.25, N 6.89.
Example 14
4-(3,4-Dichlorophenyl)-2-[2-(4-methvlpiperazin-1-vl)-benzvlidene1thiomorpholin-3-one
M.p. 171-173°C. Mass spectrum 448 (M+1).
Converting to the hydrochloride salt, using 1 .OM HCl in ether, and recrystaliizing from isopropanol gave pale yellow crystals.
j5 M.p. 155-157°C. Elemental analysis calculated for C22H23N3OSCI2«HCI-1.5H2O:
C 51.62, H 5.32, N 8.21. Found: C 51.81, H 5.02, N 8.45.
Example 15
4-(3,4-Dichlorophenvl)-2-r2-(4-methvlpiperazin-1-vl)-benzyl-thiomorpholin3-one hydrochloride trihydrate
A slurry of 4-(3,4-dichlorophenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]thiomorpholin-3-one in (201 mg, 0.5 mmol) 3 mL of anhydrous methanol (3 ml) was treated with samarium iodide (Sml2) (15 ml of 0.1 m) in THF (Aldrich Chemical Co., Milwaukee, WI) and stirred overnight at room temperature under a nitrogen atmosphere. An additional 5 mL of Sml2 solution was added and,-after an additional one hour, the solvent was removed in vacuo and the residue was flash chromatographed using ethyl acetate/methanol to elute the free base of the product. The hydrochloride salt was prepared, using 1.0M HCl in ether, to produce a light tan solid.
M.p. 105-110°C (foam). Elemental analysis calculated for
C22H25N3OSCI2«HCI«3 H2O: C 48.85, H 5.96, N 7.77. Found: C 48.95, H 5.58, N 7.51. 1H-NMR (CDCI3, 400 MHz, free base) 6 7.45-7.41 (2H, m), 7.17-7.13 (2H, m), 7.06 (1H, t); 4.16 (1H, m), 4.00-3.86 (2H, m), 3.53 (1H, dd), 3.10-2.95 (7H, m), 2.61 (4H, br s), 2.37 (3H, s).
AP/P/ 97/01107
AP.00769
-61Example 16
4-Methyl-2-r2-(4-methylpiperazin-1-vl)-benzvlidenel-thiomorpholin-3-one hydrochloride hemihydrate.
Under a nitrogen atmosphere, sodium hydride (49 mg, 1.24 mmol, 60% oil 5 dispersion) was washed with hexanes and layered with 6 mL of anhydrous THF.
After cooling to 0°C, 2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one (250 mg, 0.825 mmol) was added and the reaction was stirred for 30 min. To the resulting solution was added iodomethane (62 pL, 0.99 mmol), followed 15 minutes later by an additional 10 //L of iodomethane. After 30 min., the solvent was removed in vacuo and the residue was dissolved in methylene chloride and washed with aqueous ammonium chloride and aqueous brine. After drying, the solvent was removed in vacuo and the residue was purified by flash chromatography. The free base was converted into the hydrochloride salt as described in Example 15 to produce the title product as a pale yellow solid.
M.p. 236-238°C. Mass spectrum 318 (M+1). 1H-NMR (DMSO-d6 + D2O 400
MHz) δ7.70 (1H, s), 7.48 (1H, d), 7.30 (1H, t), 7.11-7.04 (2H, m), 3.69 (2H, br s), 3.55-3.30 (2H, br s), 3.29-3.02 (4H, m), 2.97 (3H, s), 2.90 (4H, br s), 2.79 (3H, s). Elemental analysis calculated for C17H23N3OS’HCI*0.5 H2O: C 56.26, H 6.94, N 11.58. Found: C 56.22, H 7.11, N 11.37
Example 17
4-(3,4-Dichlorophenyl)-2-(2-piperazin-1-vlbenzvlidene)-thiomorpholin-3-one.
Under a nitrogen atmosphere, a mixture of 4-(3,4-dichlorophenyl)-2-[2-(4methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one (338 mg, 0.756 mmol) in 9 mL of anhydrous 1,2-dichloroethane was treated with σ-chloroethyl chJoroformate (98 pL
0.907 mmol) and refluxed overnight. The’solvent was then removed in vacuo and 10 mL of methanol was added and refluxed for 30 minutes. Following removal of the solvent, the residue was extracted into methylene chloride and washed with saturated aqueous sodium carbonate (Na2CO3) and saturated brine, dried with magnesium sulfate and concentrated to a foam. Flash chromatography using triethyl amine/methanol/ethyl acetate (1:2:97) gave the purified free base of the title compound.
M.p. 198-200°C. Mass spectrum 434 (M+1), 436. Elemental analysis calculated for C21H21N3OSC!2: C 58.07, H 4.87, N 9.67. Found: C 57.93, H 4.71, N 9.43.
AP/P/ 9 7/01107
AP.00769
-62Conversion to the hydrochloride salt using 1M HCI in CH3OH, followed by recrystallization from isopropanol, gave a crystalline solid, m.p. 154-155°C.
Preparation 1
2-(4-Methylpiperazin-1-vl)-benzaldehyde
This compound was prepared using the methods of W. Nijhuis et al, Synthesis,
641-645 (1987) or J. Watthey et al, Journal of Medicinal Chemistry, 26, 1116-1122 (1983).
In the same manner as the preparation of 2-(4-methylpiperazin-1-yl)-benzaldehyde, the following analogs were also prepared:
4,6-Dibromo-2-(4-methylpiperazin-1-vl)-benzaldehvde
72% yield. M.p. 92-93°C. Mass spectrum 362. 1H-NMR (CDCI3, 250 MHz) δ
10.12 (1H, s), 7.44 (1H, d), 7.16 (1H, d), 3.10 (4H, br s), 2.61 (4H, s), 2.36 (3H, s). 6-Fluoro-2-(4-methvlpiperazin-1-vl)-benzaldehyde
69% yield. Light brown oil. Mass spectrum 223 (M+1). 1H-NMR (CDCI3, 250
MHz) δ 10.27 (1H, s), 7.45 (1H, m), 7.86 (1H, d), 6.75 (1H, dd), 3.14 (4H, t), 2.62 (4H, t), 2.37 (3H, s).
Preparation 2
2,4-Dibromo-6-fluoro-benzaldehvde.
In a flame-dried 250 mL round-bottomed flask equipped with an addition funnel and magnetic stirrer, a mixture of diisopropylamine (4.82 mL, 34.66 mmol) in 100 mL of anhydrous THF was cooled to -78°C and treated with 2.5N n-butyllithium (13.86 mL, 34.66 mmol) in THF, dropwise. After stirring for 10 minutes a mixture of 3,5-dibromo-1fiuorobenzene (8.0 g, 31.51 mmol) in 16 mL of THF was added dropwise and stirring was continued for an additional 30 minutes. At this point, N,N-dimethylformamide (DMF) (2.68 mL, 34.66 mmol) was added dropwise and stirring continued another 10 minutes at -78°C. The reaction was quenched with saturated aqueous ammonium chloride and the solvent removed on a rotary evaporator. The residue was dissolved in ether, washed with saturated brine and dried over calcium sulfate, filtered and concentrated to an oil, 7.36 g. Purification by flash chromatography using ethyl acetate-hexanes (1:99) gave the title product as a white solid.
M.p. 57-58°C. Mass spectrum 281 (M+1), 283. 1H-NMR (CDCI3, 400 MHz) δ
10.29 (1H, s), 7.66 (1H, t), 7.33 (1H, dd). Elemental analysis calculated for C7H3Br2FO: C 29.82, H 1.07. Found: C 30.25, H 1.03.
AP/P/ 9 7/01107
AP.00769
-63Preparation 3
3- (4-Chlorobenzyl)-imidazolidine-2,4-dione
Under a nitrogen atmosphere in a flame-dried flask, with magnetic stirring, the potassium salt of imidazolidine-2,4-dione (1.382 g, 10 mmol) and 4-chlorobenzyl bromide (2.055 g, 10 mmol) were combined with 15 mL of anhydrous Ν,Ν-dimethylformamide (DMF) and heated to 170-175°C for 5 hours. The reaction was then cooled to room temperature and poured over 50 mL of water to produce a waxy white precipitate. Recrystallization from ethyl acetate : hexanes produced the title product as a white crystalline solid, 0.775 g (34.5%).
M.p. 162-163.5°C (dec.). Ή-NMR (DMSO-d6) <58.17 (1H, s), 7.34 (4H, q), 4.51 (2H, s), 3.98 (2H, s), 3.35 (HOD, s).
In the same manner, the potassium salt of thiazolidine-2,4-dione (1.0 g, 6.45 mmol) was converted to 3-(4-chIorobenzyl)-thiazolidine-2,4-dione , 0.97 g (62%).
Ή-NMR (CDCI,, 250 MHz) <5 7.32 (4H, sym m), 4.73 (2H, 2), 3.95 (2H, s).
Preparation 4
4- (3,4-Dichlorophenyl)-thiomorpholin-3-one
Under a nitrogen atmosphere in a flame-dried flask, sodium hydride (72 mg, 1.79 mmol, 60% oil dispersion) was washed with hexanes and then treated with 6 mL of anhydrous DMF, and cooled to 0°C. Thiomorpholin-3-one (200 mg, 1.71 mmol) was added in one portion with stirring. After gas evolution had stopped (ca. 30 min), 4-iodo-1,2-dichlorobenzene (700 mg, 2.56 mmol) was added, followed after 5 minutes by copper (I) bromide (490 mg, 3.42 mmol). After heating at 75°C overnight, the mixture was partitioned between ethyl acetate and 1N lithium chloride, filtered through diatomaceous earth and combined with additional ethyl acetate washes of the diatomaceous earth filter cake. The organic layers were washed with additional 1N lithium chloride, brine (saturated sodium chloride) and dried over calcium sulfate (CaSO4). Concentration in vacuo gave 363 mg of light brown oil which was flash chromatographed (30-50% ethyl acetate in hexanes) to give a white solid, 108 mg.
Ή-NMR (CDCIj, 400 MHz) <5 7.44 (1H, d), 7.37 (1H, s), 7.12 (1H, dd), 3.93 (2H,
t), 3.43 (2H, s), 3.01 (2H, t).
L 0 U 0 / L 6 /d/dV
AP.00769
-64Preparation 5
4-(4-Trifluoromethvlphenyl)-thiomorpholin-3-one.
A mixture of thiomorphoiin-3-one (500 mg, 4.27 mmol), 4-trifIuoromethyl-1iodobenzene (1.25 mL, 8.5 mmol) and copper metal (814 mg, 12.8 mmol) was heated in a sealed glass tube at 185-200°C for 18 hours. The residue was then purified by flash chromatography to give 260 mg of the title product as a white solid.
M.p. 85-87°C. Mass spectrum 262 (M+1). 1H-NMR (CDCI3, 400 MHz) δ 7.62 (2H, d), 7.37 (2H, d), 3.97 (2H, t), 3.43 (2H, s), 3.01 (2H, t).
In the same manner, 4-(3,4-dichlorophenyl)-thiomorphoIin-3-one was 10 prepared using copper bronze (Aldrich Chemical Co., Milwaukee, Wl) and heating in a round bottomed flask under nitrogen atmosphere at 170° in 37-46% isolated yield,
m.p. 79-80°C.
Preparation 6
4-Benzylthiomorpholin-3-one
Under a nitrogen atmosphere in a flame-dried flask, sodium hydride (4.65 g,
0.105 mol, 54% oil dispersion) was added to 150 mL of anhydrous dimethylformamide (DMF), and the suspension was cooled to 0°C. Thiomorpholin-3-one (11.7 g, 0.1 mol) was added in portions over 30 minutes with stirring. After gas evolution had stopped (ca. 30 minutes), benzyl chloride (12.1 g, 0.105 mol) in DMF (50 mL) was added and stirring was continued at room temperature overnight. The reaction was then warmed to 80°C for 15 minutes and cooled. Water (250 mL) was added and the mixture was extracted with chloroform which was dried (MgSOJ and concentrated in vacuo to an oil. The oil was triturated with ethyl ether (Et2O) and cooled by dry ice to give the product, 12.75 g as a solid, m.p. 60-62°C.
Recrystallization of 5 g from 100 mL of Et2O gave 3.5 g of pure product, m.p.
62-63°C along with a second crop of 0.75 g with m.p. 62-63°C.
In the same manner, 4-(3,4-dichlorobenzyl)-thiomorphoiin-3-one was prepared in 89% yield from 3,4-dichlorobenzyl bromide and thiomorpholin-3-one as a white solid.
' M.p. 86-87°C. 1H-NMR (CDCI3, 400 MHz) δ 7.38 (1H, d), 7.33 (1H, d), 7.10 •(1H, dd), 4.56 (2H, s), 3.55-3.51 (2H, m), 3.37 (2H, s), 2.81-2.76 (2H, m).
AP/P/ 9 7/01107
1.
ΑΡ θ Ο 7 6 9H;u-ing n°'v par‘‘cu:!!rly and ascertained niy/our said invention and ia v ;··,·!( iitatiiter the same is to Lc j crlbnncd i/'.'.e declare that what l/v.c ciaini is —

Claims (5)

A compound of the formula wherein R1 is a group of the formula G1, G2, G3, G4, G5, G6 or G7 depicted below, AP/P/ 9 7/01107 AP.00769 G6 G7 AP/P/ 9 7/01 107 a is zero to eight; each R13 is, independently, (C,-C4)alkyl or a (C1-C4)methylene bridge from one of the ring carbons of the piperazine or piperidine ring of G1 or G2, respectively, to the 30 same or another ring carbon or a ring nitrogen of the piperazine or piperidine ring of -G1 or G2, respectively, having an available bonding site, or to a ring carbon of R6 having an available bonding site; E is oxygen, sulfur, SO or SO2; AP.00769 -67X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C.,-C6)alkyl, hydroxy, trifiuoromethyl, (C^Cgjalkoxy, -SO,(C.,-C6)alkyl wherein t is zero one or two, -CO2R10 or -CONR11R12; Y is an optionally substituted (CrC4) heteroalkyl bridge that, together with the 5 atoms to which it is attached, forms a five to seven membered heterocycle containing two to four heteroatoms selected from the group consisting of 1,3-oxazolidin-4-on-5-yl,
1.3- oxazolidin-2,4-dion-5-yl, 4,5-dhydro-1,2-oxazolidin-3-on-4-yl, 1,3-thiazolidin-4-on-5yl, 1,3-thiazolidin-2,4-dion-5-yl, 1,3-imidazolidin-4-on-5-yl, 1,3-imidazolidin-2,4-d:on-510 yl, 1,2-pyrazolidin-3-on-4-yl, 1,2-thiazolidin-1,1,3-trion-4-yl, 1,2-thiazoiidin-3-on-4-yl, tetrahydro-1,2-oxazin-3-on-4-yl, tetrahydro-1,3-oxazin-4-on-5-yI, tetrahydro-1,3-oxazin2.4- dion-5-yl, morpholin-3-on-2-yl, morpholin-3,5-dion-2-yl, 2,3-dihydro-1,4-oxazin-3on-2-yl, tetrahydro-1,3-thiazin-4-on-5-yl, tetrahydro-1,3-thiazin-2,4-dion-5-yl, tetrahydro-1,2-thiazin-3-on-4-yi, thiomorpholin-3-on-2-yl, thiomorpholin-3,5-dion-2-yl,
15 2,3-dihydro-1,4-thiazin-3-on-2-yl, hexahydro-1,2-diazin-3-on-4-yl, 4,5-dihydro-2Hpyridazin-3-on-4-yl, hexahydro-1,3-diazin-4-on-5-yl, hexahydro-1,3-diazin-2,4-dion-5-yl, piperazin-2-on-3-yl, piperazin-2,6-dion-3-yl, tetrahydro-1,3,4-thiadiazin-5-on-6-yl, 5,6dihydro-1,3,4-thiadiazin-5-on-6-yl, 1,3,4-oxadiazin-5-on-6-yl, 5,6-dihydro-1,2,4oxadiazin-5-on-6-yl, tetrahydro-1,2,4-oxadiazin-5-on-6-yl, 1,2,4-triazin-5-on-6-yl,
20 tetrahydro-1,2,4-oxadiazin-5-on-6-yl, 5,6-dihydro-1-2,4-oxadiazin-5-on-6-yl, 1,2,4oxadiazin-3,5-dion-6-yl, 1,2,4-trazin-6-on-5-yl, hexahydro-1,2-oxazepin-3-on-2-yl, hexahydro-1,3-oxazepin-4-on-5-yl, hexahydro-1,4-oxazepin-3-on-2-yl, hexahydro-1,4oxazepin-3,5-dion-2-yi, hexahydro-1,4-oxazepin-3,5-dion-6-yl, 2,3,5,6-tetrahydro-1-4oxazepin-5,7-dion-6-yl, hexahydro-1,4-oxazepin-5-on-6-yl, hexahydro-1,3-oxazepin25 2,4-dion-5-yl, hexahydro-1,2-thiazepin-3-on-4-yI, hexahydro-1,4-thiazepin-3-on-2-yl,
1.2- pyrazolidin-3-on-4-yl, 1,2-thiazolidin-1,1,3-trion-4-yl, 1,2-thiazolidin-3-on-4-yl, 10 tetrahydro-1,2-oxazin-3-on-4-yl, tetrahydro-1,3-oxazin-4-on-5-yl, tetrahydro-1,3-oxazin2.4- dion-5-yl, morphoiin-3-on-2-yl, morpholin-3,5-dion-2-yI, 2,3-dihydro-1,4-oxazin-3on-2-yl, tetrahydro-1,3-thiazin-4-on-5-yl, tetrahydro-1,3-thiazin-2,4-dion-5-yl, tetrahydro-1,2-thiazin-3-on-4-yl, thiomorpholin-3-on-2-yl, thiomorpholin-3,5-dion-2-yl,
1.3- oxazolidin-2,4-dion-5-yl, 4,5-dihydro-1,2-oxazolidin-3-on-4-yl, 1,3-thiazolidin-4-on-5yl, 1,3-thiazolidin-2,4-dion-5-yl, 1,3-pyrazolidin-4-on-5-yl, 1,3-imidazolidin-2,4-dion-5-yl,
2-[2-(4-Cyclopropylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)25 thiomorpholin-3-one.
12. A pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache,
30 migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette
AP/P/ 9 7/01107
AP.00769
-78syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
5
13. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
10
14. A method for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s
15 diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia,'premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal in need of such treatment or prevention an
20 amount of a compound according to claim 1 that is effective in treating or preventing such disorder or condition.
15. A method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, comprising administering to a mammal in need of such treatment or prevention an
25 amount of a compound according to claim 1 that is effective in treating or preventing such disorder or condition.
16. A pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature
30 ejaculation, eating disorders, obesity, chemical dependencies, cluster headache,
-migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia,
AP/P/ 9 7/01107
I
AP.00769
-79premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, comprising a serotonin receptor antagonizing or agonizing effective amount of a compound according to claim 1 and a
5 pharmaceutically acceptable carrier.
17. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, comprising a serotonin receptor antagonizing or agonizing effective amount of a compound of according to claim 1 and a
10 pharmaceutically acceptable carrier.
18. A method for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer’s disease,
15 obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal,
20 comprising administering to a mammal requiring such treatment or prevention a serotonin receptor antagonizing or agonizing effective amount of a compound according to claim 1.
19. A method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal,
25 comprising administering to a mammal requiring such treatment or prevention a serotonin receptor antagonizing or agonizing effective amount of a compound according to claim 1.
20. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic
30 neurotransmission in a mammal, comprising:
a) a pharmaceutically acceptable carrier;
b) ' a compound of according to claim 1; and
c) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof;
AP/P/ 9 7/01107
AP.00769
-80wherein the amount of the active compounds are such that the combination is effective in treating or preventing such disorder or condition.
21. A method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal,
5 comprising administering to a mammal requiring such treatment or prevention:
a) a compound according to claim 1 ; and
b) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof; wherein the amounts of the active compounds are such that the combination is effective in treating or preventing such disorder or condition. .
10
22. A pharmaceutical composition according to claim 20, wherein the 5-HT re-uptake inhibitor is sertraline or a pharmaceutically acceptable salt thereof.
23. A method according to claim 21, wherein the 5-HT re-uptake inhibitor is sertraline or a pharmaceutically acceptable salt thereof.
24. A method for treating or preventing a disorder or condition selected from
15 hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract
20 disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal requiring such treatment or prevention:
a) a compound according to claim 1 ; and
25 b) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating or preventing such disorder or condition.
25. A method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal,
30 comprising administering to said mammal requiring such treatment or prevention:
a) a 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and
b) ' a 5-HT10 antagonist of formula I or a pharmaceutically acceptable salt thereof;
L 0 L I· 0 / L 6 /d/dV
AP . 0 0 7 6 9
-81wherein the amounts of the active compounds are such that the combination is effective in treating or preventing such disorder or condition.
26. A method for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress
5 syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer’s disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia
10 Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal requiring such treatment or prevention:
a) a 5-HT.a antagonist or a pharmaceutically acceptable salt thereof; and
b) a 5-HT.d antagonist of formula I or a pharmaceutically acceptable salt
15 thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating or preventing such disorder or condition.
27. A pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic
20 neurotransmission in a mammal, comprising:
a) a 5-HT.a antagonist or a pharmaceutically acceptable salt thereof; and
b) a 5-HT1D antagonist of formula I or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds are such that the combination is
25 effective in treating or preventing such disorder or condition.
28. A pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache,
30 migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson’s diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette
AP/P/ 9 7/01 107
AP.00769
-82syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, comprising:
a) a 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and
b) a 5-HT1D antagonist of formula I or a pharmaceuticaliy acceptable salt
2-(2-(3,5-Dimethyipiperazin-1-yl)-benzylidene]-4-phenylthiomorpholin-3-one; 4-(3,4-Dichlorophenyl)-2-[2-(4-methy lpiperazin-1-yl)-benzylidene]-thiomorpholin15 3-one;
’ i
2-(2-(3,5-Dimethylpiperazin-1-yl)-benzylidene}-4-(4-fluorophe.nyl)-thiomorpholin-310 one;
2-(2-(4-Cyclopropylpiperazin-1-yl)-benzylidene]-4-(3,4-difluorophenyl)thiomorpholin-3-one;
30 2-(2-(4-Cyclo propy Ipipe razin-1-yl)-benzylidene]-4-(3,5-dichlorophenyl)- thiomorpholin-3-one;
2-[2-(4-Cyclopropylpiperazin-1-yl)-benzylidene]-4-pyridin-3-yl-thiomorpholin-3one;
2-[4-Bromo-2-‘(4-methylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)thiomorpholin-3-one;
2-[2-(4-tert-Buty Ipiperazin-1-y l)-benzylide ne]-4-(3,4-dichlorophenyl)thiomorpholin-3-one;
AP/P/ 9 7/01107
AP.00769
-763-(3,4-Dichlorophenyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiazolidin-4one;
2-[5-Fluoro-2-(4-methylpiperazin-1-yl)-benzyIidene]-4-phenyl-thiomorphoIin-3one;
30 ' 4-Benzo[1,3]dioxol-5-yl-2-[2-(3,5-dimethyIpiperazin-1-yl)-benzylidene]thibmorpholin-3-one;
2-{hydroxy-[2-(4-methylpiperazin-1-yI)-phenyl]methyl}-4-(4-trifluoromethylphenyl)thiomorpholin-3-one;
20 2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]methyl}-thiomorpholin-3-one;
2,3,4,5-tetrahydro-1,4-thiazepin-3-on-2-yl, hexahydro-1,4-thiazepin-3,5-dion-2-yi, hexahydro-1,4-thiazepin-3,5-dion-6-yl, 2,3,6,7-tetrahydro-1,4-thiazepin-5-on-6-yl, 6,7dihydro-1,4-thiazepin-5-on-6-yl, hexahydro-1,3-thiazepin-2,4-dion-5-yl, hexahydro-1,2diazepin-3-on-4-yl, hexahydro-1,3-diazepin-2,4-dion-5-yl, hexahydro-1,4-diazepin-2-on30 3-yl, hexahydro-1,4-diazepin-5-on-6-yl, hexahydro-1,4-diazepin-5,7-dion-6-yl, •hexahydro-1,3,5-thiadiazepin-2,6-dion-7-yl,4,5,6,7-tetrahydro-1-3,5-thiadiazepin-6-on7-yl, and 2',3,5,6-tetrahydro-1,2,4-triazepin-3,5-dion-7-yl; wherein the substituents on any of the carbon atoms capable of supporting an additional bond, of said (C,-C4)
L 0 I I 0 / L 6 Zd/dV
AP.00769
-73heteroalkyl bridge, are chloro, fluoro, (C^Cgjalkyl, (CrC5)alkoxy, trifluoromethyl or cyano; wherein the substituents on any of the nitrogen atoms capable of supporting an additional bond, of said (CrC4) heteroalkyl bridge, are (C^Cgjalkyl or trifluoromethyl;
R2 is hydrogen, (C,-C4)alkyl, phenyi or naphthyl, wherein said phenyl or naphthyl 5 may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C.,-C6)alkyl, (C^Cgjalkoxy, trifluoromethyl, cyano and
-SOJC^-Cgjalkyl wherein k is zero, one or two;
R3 is -(CH2)mB, wherein m is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four hetero
10 atoms in the ring, and wherein each of the foregoing phenyl, naphthyl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C^Cgjalkyl, (C^Cgjalkoxy, (C1-Ce)alkoxy-(C1C6)alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, -COOH and -SO^C,CE)alkyl wherein n is zero, one or two;
15 FR6 is selected from the group consisting of hydrogen, (C.-Cgjalkyl optionally substituted with (C.,-C6)alkoxy or one to three fluorine atoms, or [(Cn-C4)alkyl]aryl wherein the aryl moiety is phenyi, naphthyl, or heteroaryl-(CH2)q-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one,
20 two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C^Cgjalkyi, (C^Cgjalkoxy, trifluoromethyl, cyano and -SOg(C,-Ce)alkyl, wherein g is zero, one or two;
R7 is selected from the group consisting of hydrogen,. (C^Cgjalkyl, [(C,25 C4)alkyi]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)r-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and r is zero, one, two, three or four, and wherein said aryl and heteroaryi moieties may optionally be substituted with one or more substituents independently selected from the group
30 consisting of chloro, fluoro, bromo, iodo, (C^CgJalkyl, (C^Cgjalkoxy, trifluoromethyl, C(=O)-(C1-C6)alkyl, cyano and -SO^C^Cgjalkyl, wherein j is zero, one or two;
or R6 and R7 taken together form a 2 to 4 carbon chain;
R8 is hydrogen or (C^Cjjalkyl;
AP/P/ 9 7/01 107
AP.00769
-74R9 is hydrogen or (C,-C6)alkyl;
or Rs and Rs, together with the nitrogen atom to which they are attached, form a 5 to 7 membered heteroaikyl ring that may contain from one to four heteroatoms selected from nitrogen, sulfur and oxygen;
5 and p is one, two, or three;
each of R10, R11 and R12 is selected, independently, from the radicals set forth in the definition of R2; or R11 and R12, together with the nitrogen to which they are attached, form a 5 to 7 membered heteroaikyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen; and .
10 the broken lines indicate optional double bonds, with the proviso that when the broken line in G2 is a double bond that R8 is absent.
11. A compound according to claim 10, wherein said compound is selected from the group consisting of;
2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one;
2-(2-(4-methy Ipipe razin-1 -y I )-benzy lid ene]-4-(4-trifluoromethylphenyl)thiomorpholin-3-one;
2. A compound according to claim 1, wherein R1 is j—N N-R6,
15 \_/
G1
R6 is methyl and R2 is hydrogen.
2.3- dihydro-1,4-thiazin-3-on-2-yl, hexahydro-1,2-diazin-3-on-4-yl, 4,5-dihydro-2H15 pyridazin-3-on-4-yl, hexahydro-1,3-diazin-4-on-5-yl, hexahydro-1,3-diazin-2,4-dion-5-yl, piperazin-2-on-3-yl, piperazin-2,6-dion-3-yl, tetrahydro-1,3,4-thiadiazin-5-on-6-yl, 5,6dihydro-1,3,4-thiadiazin-5-on-6-yl, 1,3,4-oxadiazin-5-on-6-yl, 5,6-dihydro-1,2,4oxadiazin-5-on-6-yl, tetrahydro-1,2,4-oxadiazin-5-on-6-yl, 1,2,4-triazin-5-on-6-yl, tetrahydro-1,2,4-oxadiazin-5-on-6-yl, 5,6-dihydro-1-2,4-oxadiazin-5-on-6-yl, 1.2,420 oxadiazin-3,5-dion-6-yl, 1,2,4-trazin-6-on-5-yl, hexahydro-1,2-oxazepin-3-on-2-yl, hexahydro-1,3-oxazepin-4-on-5-yl, hexahydro-1,4-oxazepin-3-on-2-yl, hexahydro-1,4oxazepin-3,5-dion-2-yl, hexahydro-1,4-oxazepin-3,5-dion-6-yl, 2,3,5,6-tetrahydro-1-4oxazepin-5,7-dion-6-yl, hexahydro-1,4-oxazepin-5-on-6-yl, hexahydro-1,3-oxazepin2.4- dion-5-yl, hexahydro-1,2-thiazepin-3-on-4-yl, hexahydro-1,4-thiazepin-3-on-2-yl,
25 2,3,4,5-tetrahydro-1,4-thiazepin-3-on-2-yl, hexahydro-1,4-thiazepin-3,5-dion-2-yl, hexahydro-1,4-thiazepin-3,5-dion-6-yl, 2,3,6,7-tetrahydro-1,4-thiazepin-5-on-6-yl, 6,7dihydro-1,4-thiazepin-5-on-6-yl, hexahydro-1,3-thiazepin-2,4-dion-5-yl, hexahydro-1,2diazepin-3-on-4-yI, hexahydro-1,3-diazepin-2,4-dion-5-yl, hexahydro-1,4-diazepin-2-on3-y I, hexahydro-1,4-diazepin-5-on-6-yl, hexahydro-1,4-diazepin-5,7-dion-6-yl,
30 hexahydro-1,3,5-thiadiazepin-3-on-7-yl, 4,5,6,7-tetrahydro-1-3,5-thiadiazepin-6-on-7-yl, and 2,3,5,6-tetrahydro-1,2,4-triazepin-3,5-dion-7-yl; wherein the substituents on any of the carbon atoms capable of supporting an additional bond, of said heteroalkyl bridge, are chloro, fluoro, (C.,-C6)alkyl, (C^C^alkoxy, trifiuoromethyl or
AP/P/ 9 7/01107
AP.00769
-68cyano; wherein the substituents on any of the nitrogen atoms capable of supporting an additional bond, of said (C,-C4) heteroalkyl bridge, are (C^Cgjalkyl or trifluoromethyl;
R2 is hydrogen, (C1-C4)alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents independently selected
5 from chloro, fluoro, bromo, iodo, (C^Cgjalkyl, (C^C^alkoxy, trifluoromethyl, cyano and -SOk(C,-C6)alkyl wherein k is zero, one or two;
R3 is -(CH2)mB, wherein m is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four heteroatoms in the ring, and wherein each of the foregoing phenyl, naphthyl and heteroaryl
10 groups may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C^Cgjalkyl, (C.,-C6)alkoxy, (ΟΓΟ6) alkoxy^C,C6)alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, -COOH and -SO^C,C6)alkyl wherein n is zero, one or two;
Re is selected from the group consisting of hydrogen, (C^CJalkyl optionally
15 substituted with (C^C^alkoxy or one to three fluorine atoms, or [(C^CJalkyljaryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)q-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be
20 substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C.,-CB)alkyl, (C^C^alkoxy, trifluoromethyl, cyano and -SOg(C.,-C6)alkyl, wherein g is zero, one or two;
R7 is selected from the group consisting of hydrogen, (C^CJalkyl, [(C,C4)alkyl]a ry I wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)r-, wherein
25 the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and r is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or- more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C.,-C6)alkyl, (C^CJalkoxy, trifluoromethyl, 30 C(=O)-(C1-C6)alkyl, cyano and -SO^C-j-C^alkyl, wherein j is zero, one or two;
or R6 and R7 taken together form a 2 to 4 carbon chain;
R8 is' hydrogen or (C1-C3)alkyl;
R9 is hydrogen or (C.,-C6)alkyl;
AP/P/ 9 7/01 107
AP.00769
-69or R6 and Rs, together with the nitrogen atom to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen;
and p is one, two, or three;
5 each of R10, R11 and R12 is selected, independently, from the radicals set forth in the definition of R2; or R11 and R12, together with the nitrogen to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen; and the broken lines indicate optional double bonds, with the proviso that when the
10 broken line in G2 is a double bond that R8 is absent;
or a pharmaceutically acceptable salt thereof.
3- (4-(3,4-Dichlorophenyl)-3-oxo-thiomorpholin-2-ylidenemethyl]-6-dimethylamino2-(4-methylpiperazin-1-yl)-benzonitrile;
5 5-[2-(4-Methylpiperazin-1-yl)-benzylidene]-2-phenylthiazolidin-4-one;
3- (4-triflu oro methy Ipheny l)-5-[2-(4-methylpiperazin-1 -yl)-benzylidene]15 thiazolidine-2,4-dione;
3-(4-chlorophenyl)-5-[2-(4-methylpiperazin-1-y()-benzylidene]-thiazoiidine-2,4dione;
3- {4-chlorobenzyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiazolidine-2,4dione;
3-(4-chlorobenzyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-imidazolidine-2,4dione;
5 3-(4-chlorophenyl)-5-[2-(4-methylpiperazin-1-yl)-benzylidene]-imidazolidine-2,4dione;
3. A compound according to claim 1 wherein Y together, with the atoms to 20 which it is attached, forms an optionally substituted five to seven membered heterocycle selected from 1,3-thiazolidin-2,4-dion-5-yI, 1,3-imidazolidin-2,4-diori-5-yl, thiomorpholin-3-on-2-yi or morpholin-3-on-2-yl.
4-(3,4-Dichloropheny 1)-2-(2-(2,4,6-trimethylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one; and
4-(3,4-DichiorophenyI)-2-(2-(3-dimethylaminopyrrolidin-1-yl)-benzylidene]thiomorpholin-3-one;
20 4-(3,4-Dichlorophenyl)-2-[2-(4-methyl-[1,4]diazepan-1-yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(3-dimethylaminopyrroIidin-1-yl)-benzylidene]thiomorpholin-3-one;
4-Benzo[1, 3]d i oxo l-5-y 1-2-(2-(2,5-dimethylpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
4-Benzo[1,3]dioxol-5-yl-2-[2-(4-cyclopropylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(3-methylaminopyrrolidin-1-yl)-benzy lidene]thiomorpholin-3-one;
5 4-(3,4-Difluorophenyl)-2-[2-(2,4,5-trimethylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Difluoropheny 1)-2-(2-(2,5-d im ethy Ipiperazi n-1 -yl)-be nzy lidene]thiomorpholin-3-one;
AP/P/ 9 7/01107
AP.00769
-774-(3,5-Dichlorophenyl)-2-[2-(2,5-dimethylpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(octahydropyrido[1,2-a]pyrazin-2-yl)-benzylidene]25 thiomorpholin-3-one;
4-(3,4-Difluoropheny 1)-2-(2-(3,4,5-trimethy lpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(1 -methylpy rrolidin-2-ylmethoxy)-benzylidene]thiomorpholin-3-one;
20 4-(3,5-Dich lo ro pheny 1)-2-(2-(3,5-dimethy Ipipe razi n-1 -yl)-be nzy lid ene]thiomorpholin-3-one;
4-(2,4-Difl u oropheny 1)-2-(2-(3,5-dimethy Ipipe razi n-1 -yl)-be nzy I ide ne]15 thiomorpholin-3-one;
4-(3,4-Difluoropheny 1)-2-(2-(3,5-dimethy Ipipe razi n-1 -yl)-benzy I ide ne]thiomorpholin-3-one;
4-(3,4-Dichlorophen yl)-2-[5-methyl-2-(4-methylpiperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
10 2-[4-Chloro-2-(4-methylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)thiomorpholin-3-one;
4- (3,4-Dichl oropheny 1)-2-(2-(3,4,5-trimethylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
4-Phenyl-2-[2-(3,4,5-trimethylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[3,6-difluoro-2-(4-methylpiperazin-1-yl)-benzylidenejthiomorpholin-3-one;
25 4-(3,4-Dichlorophenyl)-2-[2-(3,5-dim ethy I piperazin-1 -yl)-benzylidene]thiomorpholin-3-one;
4-(3,4-Dichlorophenyi)-2-(5-fluoro-2-piperazin-1-yl-benzylidene)-thiomorpholin-3one;
4-(3,4-Dichlorophenyl)-2-[2-(4-methylpiperazin-1 -yl)-benzylidene]-1-oxo20 thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(4-methy Ipiperazin-1-yl)-4-trifluoromethylbenzylidene]-thiomorpho!in-3-one;
4-(3-Chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3one;
15 2-[2-Chloro-6-(4-methylpiperazin-1-yl)-benzylidene]-4-(3,4-dichlorophenyl)thiomorpholin-3-one;
4-(4-Chlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorphoiin-3one;
4-(3,4-Dichlorophenyl)-2-[2-(4-eth ylpiperazin-1-yl)-benzylidene]-thiomorpholin-310 one;
4-(3,4-Dichlorop he nyl)-2-[2-(4-isopropy I piperazin-1 -yl)-benzylidene]thiomorphoIin-3-one;
4-(3,4-Dichlorophenyl)-2-[2-(4-methy I pipe razin-1 -yl)-5-trifluo rom ethy Ibenzylidene]-thiomorpholin-3-one;
5 4-(3,4-Dichlorophenyl)-2-{2-[4-(2-me thoxyethyl)piperazin-1 -yl]-benzylidene}thiomorpholin-3-one;
4-(3,4-Dichlorophenyl)-2-[3-fluoro-2-(4-methylpiperazin-1-yl)-benzylidene]thiomorpholin-3-one;
AP/P/ 9 7/01107
AP.00769
-754-(3,4-Dichlorophenyl)-2-[5-fluoro-2-(4-methylpiperazin-1 -yl)-benzylidene]. thiomorpho!in-3-one;
4-Benzyl-2-[2-(4-methy lpiperazin-1 -yl)-benzylidene]-1,1 -dioxothiomorpholin-330 one; '
4-(3,4-dichlorophenyl)-2-{hydroxy-[2-(4-methylpipe razin-1-yl)-phenyl]-methyl}thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]-methyl}morpholin-3-one;
25 2-{[2,4-dibromo-6-(4-methylpiperazin-1-yl)-phenyl]-hydroxymethyl}-4-(3,4dichlorophenyI)-thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-{[2-fluoro-6-(4-methylpiperazin-1-yI)-hydroxymethyl}thiomorpholin-3-one;
4-(3,4-dichlorobenzyl)-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyI]methyl}thiomorpholin-3-one;
4-benzyl-2-{hydroxy-[2-(4-methylpiperazin-1-yl)-phenyl]methyl}-thiomorpholin-315 one;
4-(3,4-dichlorophenyl)-2-(2-piperazin-1-ylbenzylidene)-thiomorphoIin-3-one. and the pharmaceutically acceptable salts of such compounds.
10. A compound of the formula
AP/P/ 9 7/01107
AP.00769 wherein R1 is a group of the formula G1, G2, G3, G4, G5, G6 or G7 depicted below,
-^Luor
AP/P/ 9 7/01 107
AP.00769
-72E is oxygen, sulfur, SO or SO2;
X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C^CgJalkyl, hydroxy, trifluoromethyl, (C.,-C6)alkoxy, -SOt(C.,-C6)alkyl wherein t is zero one or two, -CO2R10 or -CONR11R12;
5 Y.is an optionally substituted (Ο,-CJ heteroalkyl bridge that, together with the atoms to which it is attached, forms a five to seven membered heterocycle containing two to four heteroatoms selected from the group consisting of 1,3-oxazolidin-4-on-5-yl,
4-methyl-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one; and
4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1~yl)-benzylidene]-thiomorpholin3-one;
25 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)~benzyl]-thiomorpholin-3-one;
4-(3,4-dichlorophenyl)-2-[2-(4-methyipiperazin-1-yl)-benzylidenej-morpholin-3one;
4- (3,4-dichlorophenyl)-2-[2-fluoro-6-(4-methylpiperazin-1-yl)-benzylidene]20 thiomorpholin-3-one:
4- benzyl-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one;
10 4-(3,4-dichlorobenzyl)-2-[2-(4-methylpiperazin-1-yl)-benzyIidene]-thiomorpholin-3one;
4. A compound according to claim 2, wherein Y together, with the atoms to which it is attached, forms thiomorpholin-3-on-2-yl.
25 5. A compound according to claim 1, wherein R3 is optionally substituted phenyl or -(CH2)-optionally substituted phenyl.
6. A compound according to claim 2, wherein R3 is optionally substituted phenyl or -(CH2)-optionally substituted phenyl.
7. A compound according to claim 3, wherein R3 is optionally substituted 30 phenyl or -(CH2)-optionaIly substituted phenyl.
8. A compound according to claim 4, wherein R3 is optionally substituted phenyl or -(CH2)-optionally substituted phenyl.
AP/P/ 9 7/01 107
AP.00769
-709. A compound according to claim 1, wherein said compound is selected from the group consisting of;
5 thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating or preventing such disorder or condition.
APAP/P/1997/001107A 1996-09-30 1997-09-24 Aralkyl and aralkylidene heterecyclic lactams and imides. AP769A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30

Publications (2)

Publication Number Publication Date
AP9701107A0 AP9701107A0 (en) 1997-10-31
AP769A true AP769A (en) 1999-09-30

Family

ID=21835752

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001107A AP769A (en) 1996-09-30 1997-09-24 Aralkyl and aralkylidene heterecyclic lactams and imides.

Country Status (46)

Country Link
US (6) US6380186B1 (en)
EP (1) EP0929528B1 (en)
JP (1) JP3121355B2 (en)
KR (2) KR100323167B1 (en)
CN (2) CN1093123C (en)
AP (1) AP769A (en)
AR (1) AR008861A1 (en)
AT (1) ATE245630T1 (en)
AU (1) AU732451B2 (en)
BG (1) BG64484B1 (en)
BR (1) BR9713239A (en)
CA (1) CA2266107C (en)
CO (1) CO4650135A1 (en)
CZ (1) CZ295141B6 (en)
DE (1) DE69723711T2 (en)
DK (1) DK0929528T3 (en)
DZ (1) DZ2321A1 (en)
EA (1) EA002157B1 (en)
ES (1) ES2202634T3 (en)
GT (1) GT199700107A (en)
HK (1) HK1022313A1 (en)
HN (1) HN1997000135A (en)
HR (1) HRP970540B1 (en)
ID (1) ID19833A (en)
IL (2) IL129045A (en)
IS (1) IS4985A (en)
MA (1) MA26443A1 (en)
MY (1) MY125749A (en)
NO (1) NO313192B1 (en)
NZ (1) NZ334215A (en)
OA (1) OA11002A (en)
PA (1) PA8439101A1 (en)
PE (1) PE2799A1 (en)
PL (1) PL196005B1 (en)
PT (1) PT929528E (en)
RS (1) RS49699B (en)
SA (2) SA05260293B1 (en)
SI (1) SI0929528T1 (en)
SK (1) SK284704B6 (en)
TN (1) TNSN97161A1 (en)
TR (1) TR199900660T2 (en)
TW (1) TW491842B (en)
UA (1) UA56185C2 (en)
UY (1) UY24730A1 (en)
WO (1) WO1998014433A1 (en)
ZA (1) ZA978703B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
ATE273970T1 (en) * 1998-04-16 2004-09-15 Pfizer Prod Inc N-ACYL AND N-AROYL ARALKYLAMIDE
KR20010086073A (en) * 1998-12-02 2001-09-07 데이비드 존 우드 Methods and Compositions for Restoring Conformational Stability of a Protein of the p53 Family
PT1041070E (en) * 1999-03-30 2004-12-31 Pfizer Prod Inc PROCESS FOR PREPARING CYCLE THIOAMIDES
DE10022661A1 (en) 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituted benzaldehydes, process for their preparation and their use
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
WO2002078643A2 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
EP1746091A1 (en) * 2001-08-30 2007-01-24 Pfizer Products Inc. Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate
PT1288208E (en) * 2001-08-30 2006-09-29 Pfizer Prod Inc 2 - (4-ALPHO-1-PIPERAZINYL) BENZALDEIDE E-BENZYLIDENYL COMPOUNDS BY 2-FLUOROBENZALDEIDE AROMATIC NECLEOPHILIC REPLACEMENT WITH 4-ALPHA-1-PIPERAZINE IN WATER AS A SOLVENT
DK1451166T3 (en) * 2001-12-07 2005-11-14 Pfizer Prod Inc Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
AU2003214800A1 (en) 2002-01-02 2003-07-24 Ardent Pharmaceuticals, Inc. Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
EA009847B1 (en) * 2002-09-30 2008-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
ES2347152T3 (en) * 2003-11-26 2010-10-26 Pfizer Products Inc. DERIVATIVES OF AMINOPIRAZOL AS INHIBITORS OF GSK-3.
WO2005053701A1 (en) * 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
EP1697353A2 (en) * 2003-12-15 2006-09-06 Pfizer Products Incorporated Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
EA200601461A1 (en) 2004-03-17 2007-02-27 Пфайзер Продактс, Инк. NEW DERIVATIVES BENZIL (IDEN) LACTAM
AU2005238296A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
JP2007537232A (en) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク Combination of atypical antipsychotic and 5-HT1B receptor antagonist
MXPA06012347A (en) * 2004-05-21 2007-01-17 Pfizer Prod Inc Pyrazinylmethyl lactam derivatives.
WO2005113526A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
WO2006048727A1 (en) * 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006106416A1 (en) * 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
WO2007026219A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
WO2007057742A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
KR20100134063A (en) * 2008-03-25 2010-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
TWI461423B (en) 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
KR102049534B1 (en) * 2011-10-03 2019-11-27 오게다 에스.에이. NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
DE102013019618A1 (en) * 2013-11-25 2015-05-28 Avlen Georges Tri- and tetracyclic compounds for the treatment of incontinence
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110054597B (en) * 2019-04-17 2022-11-08 温州大学 Thiazolidine-4-ketone derivative synthesized under condition of no metal catalyst and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343643A2 (en) * 1988-05-25 1989-11-29 Warner-Lambert Company Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents
EP0577394A1 (en) * 1992-06-29 1994-01-05 Merck & Co. Inc. Morpholine and thiomorpholine tachykinin receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (en) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5-diisopropylbenzylidene heterocyclic compound
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (en) * 1991-06-15 1992-12-17 Basf Ag AMINOALKYL-SUBSTITUTED THIAZOLIN-2-ONE, THEIR PRODUCTION AND USE
DK0689536T3 (en) * 1993-03-16 2001-07-30 Pfizer naphtahlene
US5556841A (en) 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
KR100248643B1 (en) * 1994-06-29 2000-07-01 디. 제이. 우드 Aryl and heteroaryl alkoxynaphthalene derivatives
JP3852787B2 (en) 1995-06-01 2006-12-06 久光製薬株式会社 Thiomorpholine derivative
EP0779282A1 (en) * 1995-12-14 1997-06-18 Eli Lilly And Company Thiomorpholinone compounds for treating multiple sclerosis
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343643A2 (en) * 1988-05-25 1989-11-29 Warner-Lambert Company Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents
EP0565135A1 (en) * 1988-05-25 1993-10-13 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of imidazolidinones useful as antiallergy agents and antiinflammatory agents
EP0577394A1 (en) * 1992-06-29 1994-01-05 Merck & Co. Inc. Morpholine and thiomorpholine tachykinin receptor antagonists

Also Published As

Publication number Publication date
IL140623A0 (en) 2002-02-10
US20020091117A1 (en) 2002-07-11
US20020072519A1 (en) 2002-06-13
JP3121355B2 (en) 2000-12-25
AU3951497A (en) 1998-04-24
SA05260293B1 (en) 2006-04-18
BG103297A (en) 1999-11-30
US6627627B2 (en) 2003-09-30
PL196005B1 (en) 2007-11-30
PA8439101A1 (en) 2000-05-24
TR199900660T2 (en) 1999-07-21
AR008861A1 (en) 2000-02-23
BG64484B1 (en) 2005-04-30
CO4650135A1 (en) 1998-09-03
NZ334215A (en) 2000-09-29
YU16899A (en) 2002-03-18
NO991525L (en) 1999-05-28
ES2202634T3 (en) 2004-04-01
PT929528E (en) 2003-12-31
KR100323167B1 (en) 2002-02-04
US6921760B2 (en) 2005-07-26
US6380186B1 (en) 2002-04-30
CN1093123C (en) 2002-10-23
MY125749A (en) 2006-08-30
KR20000048731A (en) 2000-07-25
GT199700107A (en) 1999-03-23
CN1239497C (en) 2006-02-01
EP0929528B1 (en) 2003-07-23
SA97180449B1 (en) 2005-12-21
DE69723711D1 (en) 2003-08-28
CZ295141B6 (en) 2005-05-18
CN1231661A (en) 1999-10-13
PE2799A1 (en) 1999-02-04
EA199900242A1 (en) 1999-08-26
AP9701107A0 (en) 1997-10-31
ATE245630T1 (en) 2003-08-15
US20020147194A1 (en) 2002-10-10
US20020091118A1 (en) 2002-07-11
AU732451B2 (en) 2001-04-26
MA26443A1 (en) 2004-12-20
HRP970540B1 (en) 2002-08-31
SA97180449A (en) 2005-12-03
RS49699B (en) 2007-12-31
KR100346620B1 (en) 2002-07-26
SI0929528T1 (en) 2003-10-31
US6403592B1 (en) 2002-06-11
US6562813B2 (en) 2003-05-13
EP0929528A1 (en) 1999-07-21
DZ2321A1 (en) 2002-12-28
IL129045A (en) 2005-09-25
HK1022313A1 (en) 2000-08-04
DK0929528T3 (en) 2003-10-06
UA56185C2 (en) 2003-05-15
DE69723711T2 (en) 2004-02-05
US6472388B2 (en) 2002-10-29
CA2266107A1 (en) 1998-04-09
ZA978703B (en) 1999-03-30
IL129045A0 (en) 2000-02-17
IL140623A (en) 2005-03-20
HN1997000135A (en) 1998-01-28
BR9713239A (en) 2000-04-04
IS4985A (en) 1999-02-26
NO313192B1 (en) 2002-08-26
ID19833A (en) 1998-08-06
CN1329002A (en) 2002-01-02
SK41099A3 (en) 2000-09-12
CZ107199A3 (en) 2000-05-17
UY24730A1 (en) 2000-09-29
CA2266107C (en) 2002-12-03
NO991525D0 (en) 1999-03-29
SK284704B6 (en) 2005-09-08
TW491842B (en) 2002-06-21
OA11002A (en) 2001-11-06
TNSN97161A1 (en) 2005-03-15
US20020091119A1 (en) 2002-07-11
JP2000503679A (en) 2000-03-28
HRP970540A2 (en) 1998-08-31
PL332629A1 (en) 1999-09-27
EA002157B1 (en) 2001-12-24
WO1998014433A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
AP769A (en) Aralkyl and aralkylidene heterecyclic lactams and imides.
US6462048B2 (en) Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
US6423708B1 (en) Aralkyl and aralkylidene heterocyclic lactams and imides
US20050227981A1 (en) Aralkyl and aralkylidene heterocyclic lactam and imides
US20050227980A1 (en) Aralkyl and aralkylidene heterocyclic lactam and imides